Complete CV

Personal Statement

Professor Stricker is a urologist and one of the leading experts in the management and treatment of prostate cancer in Australasia. He is the Director of the St Vincent’s Prostate Cancer Centre, Chairman of the Department of Urology at St Vincent’s Private Hospital and Clinic and the Clinical Director of the Australian Prostate Cancer Research Centre in New South Wales (NSW). He is also a professor and associate professor at numerous recognised Institutions, University of Western Sydney, University of NSW and University of Sydney. His clinical practice is dedicated to the management and treatment of prostate cancer focusing on personalised care. This includes initial consultation, therapy and follow-up of all post treatment side effects including erectile dysfunction and incontinence. In 2006, Prof Stricker commenced the first robotic program using the latest technology (Da Vinci Si) in NSW at St Vincent’s Hospital. He has since performed over 6,500 radical prostatectomy cases, the largest Australasian series; more than 2,500 of which have been performed using the robotic-assisted radio guided surgery. He also has extensive experience in performing high-dose rate brachytherapy (over 1000 cases), low-dose rate brachytherapy (over 1000 cases), designing and managing structured active surveillance programs and transperineal biopsies (over 7000 cases). Prof Stricker has been leading as the Head and Chairman of the Uro-oncology Multidisciplinary team meetings for over 10 years.

He has been one of the Australian pioneers in multiparametric MRI and PSMA-PET scan imaging and introduction of focal therapy using irreversible electroporation-IRE (Nano-Knife) to treat prostate cancer and has performed over 400 cases , mentors nationally and internationally and published over 10 articles on nanoknife technology and outcomes. He has substantial experience in dealing with impotence and incontinence assessments, urodynamics and treatments including penile prosthesis, sling surgery and artificial urinary sphincter surgery.

Professor Stricker’s area of research focuses on the collection of quality of life data following treatment in order to refine surgical techniques, development and assessment of novel surgical techniques which are less invasive, the utilisation of medical imaging for the detection and evaluation of prostate cancer, and validation of nomograms to influence treatment decisions.

Professor Stricker was the driving force in setting up St Vincent’s Prostate Cancer Clinical Database and Tissue Bank in conjunction with the Garvan Institute, which is currently housed at The Kinghorn Cancer Centre. These resources contain extensive clinical and pathological outcome data and have resulted in a comprehensive scientific and clinical resource that has been acknowledged both nationally and internationally.Professor Stricker is a Member of the Australian Cancer Network working party that developed guidelines for the Management of Locally advanced and metastatic prostate cancer and PSA Testing. These guidelines have been published and used as evidence-based in publications supported by NH&MRC. Professor Stricker has authored over 200 peer-reviewed publications, has collaborative research partnerships within Australia and globally and has been involved with numerous successful grant funding applications.

Current Positions

• Emeritus Fellow, Garvan Institute of Medical Research (2020)
• Chairman, Dept. Urology, St Vincent’s Private Hospital and Clinic and HMO St Vincent’s Hospital
• Chairman, Urology, Oncology and Prostate Cancer Multidisciplinary Team at St Vincent’s Hospital
• Clinical Director, Prostate Cancer Research, The Kinghorn Cancer Centre
• Clinical Director, The Australian Prostate Cancer Research Centre – New South Wales
• Director, St. Vincent’s Prostate Cancer Research Centre
• Professor, Department of Surgery, University of New South Wales Australia
• Clinical Associate Professor, Sydney Medical School, University of Sydney
• Conjoint Professor, School of Medicine, University of Western Sydney

Tertiary Education

1978 – MBBS (Hons) University of New South Wales Australia

1980 – FRACS Part I

1980 – VQE

1988 – FRACS (Urology) Part II

Clinical Training

1979 – 1981 Junior Residency – St George Hospital

1982 – 1985 General Surgical Training and Fellowship

1986 – 1988 Urological Training and Fellowship

1989 – Visiting Urologist to St Vincent’s Hospital, Sydney

1989 – 2001 Visiting Urologist to the Royal Hospital for Women, Sydney

1989 – Visiting Urologist to St Vincent’s Private Hospital, Sydney

1989 – 2001 Visiting Urologist to the Royal Hospital for Women, Sydney

1989 – Visiting Urologist to St Luke’s Hospital, Sydney

1993 – Consultant Transplant Surgeon to St George Hospital, Sydney

2000 – Conjoint Senior Lecturer University of NSW, Sydney

2004 – Conjoint Associate Professor University of NSW, Sydney

2013 – Clinical Associate Professor Sydney Medical School, Sydney University

2014 – Clinical Professor, School of Health Sciences, University of Tasmania

2016 – Conjoint Professor, School of Medicine, University of Western Sydney

Post–Fellowship Training

• Impotence Surgical Training: Bill Furlow (Nashville), Tom Lue (San Francisco), Steve Wilson (Arkensaw)
• Pelvic Cancer Surgery: – Bill Fair and H Herr (Sloan Kettering, New York), Donald Skinner (U.S.C.), Scott Swanson, Michael Lieber, John Blasko, Joe Oesterling, Peter Scardino, Bertrand Guillaneau (St Vincent’s Hospital), Keith Kaye (Perth)
• Incontinence Surgery: – S.Raz (U.C.L.A.) – open surgery – R.Appell (Memphis) – collagen – E. Mcguire and Ann Arbour – slings
• Stone Surgery: –J.Segura (St Vincent’s Hospital), EDAP Machine (St Vincent’s Hospital), Glen Preminger (St Vincent’s Hospital)
• Ablatherm for Prostate Cancer: Gelet (France), Vallencien (France)
• Laser Prostatectomy for BPH: – Peter Gilling (St Vincent’s Hospital)
• Greenlight Laser Prostatectomy for BPH: Gordon Muir (London)
• Low Dose Rate Brachytherapy: – Michael Zelevsky (St Vincent’s Hospital), Keith Kaye (Western Australia)
• Advance Sling: – Paris June 2008
• Robotic Radical Prostatectomy: Vip Patel (St Vincent’s Hospital), Ohio State University Medical Center (Florida Hospital)
• Focal Therapy: – Prof. Mark Emberton (UCLH London)

Membership

• Urological Society of Australasia
• American Urological Association
• European Urological Society
• Prostate Cancer Foundation of Australia
• Society International d’Urologie
• Royal Australian College of Surgeons
• Australian Prostate Cancer Collaboration
• NSW Urology Oncology Group
• Multidisciplinary cancer care team (MDT)

Positions Previously Held

1992–2013 Head, Prostate Cancer Group, Garvan Institute of Medical Research/St Vincent’s Hospital Campus

1998–2012 Inaugural Director of the Prostate Cancer Foundation of Australia

2015-2020 – Conjoint Professor University Tasmania

Recent Grants Held

2010 – 2014 NHMRC Enabling Grant (ID No. 614296). “Australian Prostate Cancer Collaboration (APCC) Bio–Resource”. Clements J, Sutherland RL, Tilley W, Risbridger G, Marshall V, Roder D, Stahl J, Gardiner F, Nicol D, Frydenberg M, Pedersen J, Stricker P. $2,000,000.00

2010 – 2015 Cancer Institute NSW Program Grant for Excellence in Translational Research. Personalised medicine for cancer: molecular biomarkers in clinical decision making for breast, prostate and pancreatic cancer. CIs: Horvath LG, Kench J, Boyer M, Millar E, O’Toole S, Beith J, Grimison P. AI: Stricker P. $3,750,000.00

2012 – 2013 St Vincent’s Clinic Foundation “K & A Collins” Grant. MRI Study. Stricker P. $50,000.00

2013 – 2017 Federal Government Grant – “The Chronic Disease Prevention and Service Improvement”. Australian Prostate Cancer Research Centre NSW. Mattick J, Spigelman A, Stricker P, Hayes V, Horvath L $5,500,000.00

2016 – 2017 NHMRC Project Grant – “Epigenetic Changes in the Prostate Cancer Environment”. Clark S, Horvath L, Kench J, Stricker P et al. $848,954.00

2016 – 2017 Paul Ramsay Foundation – “Magnifi Trial”. Van Leeuwen P and Stricker P $759,000.00

2016 – 2017 Paul Ramsay Foundation – “LuPSMA Trial”. Emmett L and Stricker P $400,000.00

2017 – 2018 The John and Denise Cobcroft Cancer Research Grant/St Vincent’s Clinic Grant– “DETECT trial: Radioguided surgery with technetium99m–labelled PSMA to aid intra–operative lymph node metastases detection for patients undergoing robot–assisted radical prostatectomy and extended–pelvic lymph node dissection for prostate cancer”. Stricker P and Co–investigators $30,000.00

2017 – 2018 Commonwealth Department of Health: Cancer Control – Australian Prostate Cancer Research Centres. Stricker P, Hayes V, Horvath L, Clarke S, Kench J, Joshua A, Rasiah K, Nguyen Q $1,500,000.00

2019 – Commonwealth Department of Health: Australian Prostate Cancer Research Centre. Stricker P, Hayes V, Horvath L, Clarke S, Joshua A, Emmet L – $437,000.00

2019 – 2020 St. Vincent’s Clinic Foundation Grant. PRIMARY Trial – Can combined multiparametric MRI and PSMA PET imaging replace prostate biopsy in the primary diagnosis of prostate cancer? Emmett L and Stricker P $40,000.00

2020 – 2021 Angiodynamics (USA). IRE Immuno study $120,000

2019 – 2021 The Sydney Partnership for Health, Education, Research & Enterprise (SPHERE) – Additional diagnostic value of PSMA to mpMRI in the diagnostic setting: Ability to reduce unnecessary prostate biopsies in men being investigated for prostate cancer. PRIMARY Trial. Emmet L and Stricker P. $150,000

2019 – 2021 Cancer Institute of NSW Programme Grant $4,000,000

2021 – 2022 St. Vincent’s Clinic Foundation Grant. Prospective cross-sectional multi-centre study of 68Ga-PSMA PET/CT in addition to mpMRI in men undergoing 12-month confirmatory biopsy during Active Surveillance for low or intermediate-risk prostate cancer (PIAS Trial). Stricker P and Thompson J $25,000

2021 – 2022 Ramaciotti Health Investment Grants. Prospective cross-sectional multi-centre study of 68Ga-PSMA PET/CT in addition to mpMRI in men undergoing 12-month confirmatory biopsy during Active Surveillance for low- or intermediate-risk prostate cancer (PIAS Trial). Stricker P and Thompson J $200,00

2022 – 2022 Angiodynamics (USA). IRE Immuno study Extension $100,000

2022 St. Vincent’s Curran Foundation (Endowment Grant). PIAS study $50,000

Professional Experience

Open Radical Prostatectomy:

• Performed > 4000 cases
• Specialist in nerve sparing technique
• Mentored and trained Registrars, Fellows and Urological colleagues in nerve sparing technique
• Achieved international standard outcomes with <10% positive margins, up to 92% potency recovery and <2% long–term incontinence. These results have been presented and published in state, national and international meetings and journals

Robotic Radical Prostatectomy:

• Commenced first robotic program (Da Vinci Si) in NSW at St Vincent’s Private Hospital in February 2006 and currently has one of the largest series in Australia
• Performed > 2,600 cases.
• First robotic surgeon to perform 2,000 robotic prostatectomies in NSW and third in Australia to achieve this milestone.
• Fully trained robotic Surgeon – particular expertise in nerve sparing robotic surgery
• Performed the first Dr Vip Patel nerve sparing technique radical prostatectomy in NSW
• Invited presenter at the World Robotic Symposium Ohio 2007 and Orlando 2008 & 2010, Weill Cornell Medical College New York 2011, FOI Urology ConferenceIsrael 2012 & 2016, Urology Society of Australia and New Zealand ASM2010 & 2014, Annual Urology Scientific meeting 2009 & 2010, APCC – Robotic Masterclass 2011, Asia Pacific PCC – Robotic Masterclass 2013, Sydney Robotic Symposium – Preservation of potency in Robotic RP 2017
• Excellent results with low positive margin rate: < 1% pT2, high continence: 98% and good potency results: >70% overall (NSW Cancer Registry)
• Accredited mentor to other surgical units (Asia Pacific, Western Australia, Queensland & New Zealand)
• Associate Editor of Journal of Robotic Surgery
• Published personal series in The Journal “European Urology” 2014 & 2017, in addition to many other highly cited publications relating to robotic surgery
• Manages the Robotic Fellowship Program at St Vincent’s Private Hospital
• Invited presenter at World Robotic Symposium (2020) hosted by Royal Prince Alfred Hospital and organised by the US–Based Society of Robotic surgery (SRS), to provide masterclasses with other urologists.

Low Dose Rate Brachytherapy (Seeds):

• Personal series of > 1000 cases since 1997. One of the largest series in Australasia
• Introduced Seeds to Eastern Australia in 1996
• Results have been presented and published at national and international meetings
• Mentored and trained many of the units in Australia
• In 2001, with the support of the Urological Society of Australia arranged the acceptance of Brachytherapy as an approved item number by Medicare in the therapy for prostate cancer

High Dose Rate Brachytherapy:

• Largest personal series in Australia and one of the largest series in the world, with >1000 cases performed personally since 1998
• Presented and published at national and international meetings
• Mentored and trained multiple Urologists in the technique
• Began the first program in Australia in 1998 with Mark Stevens

Focal Therapy (HIFU & Nanoknife IRE) for localized Prostate Cancer

• Commenced HIFU in October 2005 – the first unit in Australia
• Commenced Nanoknife (IRE) in 2013 as a focal therapy
• Currently conducting quarterly workshops to train academic centres throughout Australia, New Zealand, Europe and Asia in the technique of focal NanoKnife ablation for selected patients with prostate cancer. A central registry containing all results nationally and internationally will be maintained to help evaluate and improve the utility of this technique.
• One of four international academic sites evaluating Nanoknife (IRE) focal therapy
• Performed >600 cases of Focal IRE since 2013
• Published data on the largest prospective focal Nanoknife therapy cohort in the world in European Oncology Urology. This series contained 123 patients with a minimum follow–up period of 12 months, including MRI and biopsy follow–up. These patients showed 97% clearance of cancer infield and a 10% to 12% chance of recurrence in the outfield. These are interim results as part of a cohort containing 300 cases performed by Professor Stricker.
• Mentor for US and European Centres including Mayo Clinic, Cleveland Clinic, UCLA, Cornell, Karolinska Institute and others.

Active Surveillance:

• >1000 cases on active surveillance since 1999.
• The largest series in Australia.
• Structured program of follow–up with PSA, transperineal biopsies of the prostate and MRI scans.
• Chief Investigator in evaluation of mpMRI in monitoring active surveillance
• One of 16 centres worldwide (GAP3) to share data to evaluate active surveillance

Sexual Health Rehabilitation:

• Enormous experience in sexual rehabilitation and preservation and one of the acknowledged experts in Australia
• Set up one of the largest multidisciplinary sexual dysfunction clinics in the Southern Hemisphere (the Australian Centre for Sexual Health 1991–2001)
• Trained Dr Michael Lowy who now has particular expertise in this area
• Investigator in the original research on Viagra on the protection of potency after radical prostatectomy surgery, being one of the highest accrual centers in the world and the largest in Australia.
• Currently still involved in multiple projects pertaining to sexual rehabilitation after surgery

Incontinence Therapy after Prostate Cancer Treatment:

• Personal series of >150 cases of insertion of artificial urinary sphincter for severe urinary incontinence. His experience includes the more complex artificial sphincter cases such as the use of double cuffs, complex revisions, transcorporal implantation and complex erosions. He was trained by Professor Richard Millard and Professor Robert Farnsworth.
• Post radical prostatectomy incontinence – Professor Stricker has been treating post radical prostatectomy incontinence for 30 years. He has developed a tertiary referral practice from many urologists including Dr Carlo Yuen, Dr Phillip Brenner, Dr Haxhimolla, Dr Jefferson and previously David Golovsky. Trained by Prof Millard, S Raz, Rodney Appell, Ed Mcguire and Dean Knoll.
• Large experience in the use of the ProAct Device (50–100 cases) and Collagen Implant in the treatment of minor urinary incontinence.
• Works in close association with a dedicated pelvic floor Physiotherapist Stuart Baptist in managing incontinence and post RP recovery.
• Urodynamics – Professor Stricker has personally performed a large volume of urodynamic procedures since 1988 for approximately 15 years. He was taught by Professor Richard Millard. The technique he used was video urodynamic assessment. When his practice became too busy to perform the urodynamic assessments, he continued to assess incontinent patients and referred the patients for urodynamic assessment to Professor Millard and after his retirement to Vincent Tse and then Lewis Chan.
• Sling procedures – Extensive and long experience in InVance and AdVance slings including the more recent AdVance XP sling, having performed these regularly for almost 20 years. He was trained by the initiator of the transobturator sling Dr Dean Knoll and further formal training in Paris in 2008. In addition, he has been a teacher to many urologists and trainees in sling surgery including Dr David Jefferson, Richard Savdie, Carlo Yuen, Kris Rasiah, Anthony Hutton, Phil Brenner and Peter Chin as well as his fellows and registrars.

Second Opinion Service:

• Over 20 years of experience in tailoring and personalising treatment to patient’s needs
• Initiated a large multidisciplinary team for appropriate support throughout all treatments
• Provides a comprehensive second opinion service

Transperineal Grid–directed Prostate Biopsy Technique:

• Developed and first described this technique internationally in 1997
• Over 7000 cases performed
• Has minimised the chance of post biopsy sepsis using this technique
• Has presented and published on this technique nationally and internationally
• Has mentored and trained Urologists, Fellows and Registrars in this technique
• Invited chapter in Hinman’s Atlas of Urology 4th Edition

Magnetic Resonance Imaging and Spectroscopy (MRI/MRS):

• This technique has the potential in improving the accuracy of diagnosis, minimizing invasive procedures and in monitoring patients
• First looked at the accuracy of this technology in prostate in 2007. In 2012 initiated several studies at St Vincent’s Campus evaluating MRI accuracy in comparison to prostate biopsies, PCA3 and prostate health index (PHI). Initial results from the study were presented at the AUA in San Diego in May 2013
• International and national teacher of the role of MRI in prostate cancer
• Magnetic Resonance Imaging Guided Linear Accelerator (MRI-LINAC) referred > 100 patients

PSMA PET Screening

• Initiated the first unit in New South Wales
• Published multiple prospective studies on the accuracy of this technology
• International & national speaker on PSMA
• Senior author in the multicentre PRIMARY Trial published in European Urology 2021

Clinical Trials

• Extensive experience in designing and conducting clinical trials examining the proliferation and treatment of prostate cancer and improve the accuracy of treatment of prostate cancer, particularly with the use of high–quality MRI and PET scanning.
• The results of Professor Stricker’s clinical trials have been published in numerous high impact journals and are widely cited nationally and internationally.
• Collaboration with many national and International registries and agencies to collate outcomes data on prostate cancer.
• Professor Stricker is the Chief Investigator and Principal Investigator of numerous clinical trials:
  • The DETECT Trial – This is using aGeiger counter to detect early cancer spread during the operation to more accurately remove lymph glands which may be affected by cancer more accurately.
  • The PRIMARY Trial – This trial is a multi–centre project looking at the use of PSMA PET scanning in the evaluation of patients under suspicion for prostate cancer. This trial is aiming to see if PSMA PET Scanning can improve Prostate Cancer Detection in addition to MRI Scanning, ultimately resulting in a reduction in the need to perform unnecessary biopsies. Professor Stricker isthe principal investigator with Louise Emmett
  • The MRIAS Study – An observational cohort study of multi–parametric MRI in active surveillance for low risk prostate cancer. Professor Stricker is the Chief Investigator
  • FIRE study – A prospective interventional pilot study of patients who underwent irreversible electroporation (IRE) as salvage treatment for radio–recurrent prostate cancer to assess the safety profile of IRE, as well as functional and oncological outcomes based on multi–parametric magnetic resonance imaging (mpMRI) and transperineal template mapping biopsy (TTMB) at 1year post treatment. Professor Stricker is the Chief Investigator
  • ROTI study – The use of pre–treatment prostate specific membrane antigen (PSMA) PET and Magnetic Resonance Imaging (MRI) for men with high–risk disease and pelvic lymph nodes so as to increase the therapeutic outcome at three years with minimal genitourinary (GU) and gastrointestinal (GI) toxicity. Professor Stricker isthe principal investigator with Louise Emmett
  • Quality of life (QoL) study – Assess how each treatment modality currently being offered for localized prostate cancer at St. Vincent’s Private Hospital affects the patients QOL, and how this may impact on the patient’s preference for a particular treatment.
  • IRE Immuno study – Immunomodulatory effects following focal ablation of localized prostate cancer with irreversible electroporation. Professor Stricker is the Chief Investigator.
  • PIAS study – Prospective cross-sectional multi-centre study of 68Ga-PSMA PET/CT in addition to mpMRI in men undergoing 12-month confirmatory biopsy during Active Surveillance for low- or intermediate-risk prostate cancer.
  • Mutiicentre validation of mpMRI – Retrospective Validation of Diagnostic Accuracy of mpMRI post Focal Therapy with Irreversible Electroporation (IRE). Professor Stricker is the Chief Investigator.
  • A pair matched cohort study – Retrospective observational study to assess if outcomes for active surveillance patients are similar for men with favourable risk with Gleeson 7 to those with Gleeson 6 Prostate cancer. Professor Stricker is the Chief Investigator.
  • Prognostic significance of the Index and Composite Gleason grade groups in clinically localised prostate carcinoma – Retrospective observational study to determine if the index or composite Gleason Grade Group (GGG) is a better predictor of recurrence after radical prostatectomy than the composite GGG.
  • Salvage robot-assisted radical prostatectomy after focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes
  • How does age affect urinary continence following robot-assisted radical prostatectomy? – A prospective multi-institutional study using independently collected, validated questionnaires.

Recent Awards

• Awarded Australia’s 2^nd highest award, Officer of the Order of Australia (AO) on the Australia Day 2015 Honours list for ” Distinguished service to medicine and medical research , as a leading urologist , a robotic surgery pioneer , a teacher and mentor , and as an advocate for prostate cancer awareness.”
• Top 10% downloaded publication in BJUI International for:
  • Gallium‐68‐prostate‐specific membrane antigen (68Ga‐PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate‐ and high‐risk prostate cancer
  • Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literatu re
• Top 10% downloaded publication in Journal of Magnetic Resonance Imaging for:
  • Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings
• British Journal of Urology International Global prize 2018 – Best paper published between 1 July 2016 and 30 June 2017
  • This award was received for the publication “Prospective evaluation of 68gallium–prostate–specific–membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer”.
• British Journal of Urology International Global Prize 2019 – Best paper published between 1 July 2017 and 30 June 2018
  • This award was received for the publication “Initial multicenter experience of 68gallium–PSMA PETCT guided robot–assisted salvage lymphadenectomy: acceptable safety profile by oncological benefit appears limited”.
  • The award was presented to Urology Fellow, Dr. Amila Siriwardana, at USANZ Brisbane 2019, and is reflective of the contributions being made to PSMA PET/CT research by Professor Stricker’s research team.
• European Association of Urology Best Poster – 34^th Annual EAU Congress, 15–19 March 2019, Barcelona, Spain
  • This award was received by Urology Fellow Dr. Alexandar Blazevski on behalf of Professor Stricker for the poster “Salvage irreversible electroporation for locally recurrent prostate cancer after radiotherapy – oncologic and functional outcomes”
• Urology fellow Dr. Alexandar Blazevski was awarded a High Distinction for his Master of Surgery (Urology) Thesis titled “Oncological outcomes of focal irreversible electroporation (IRE) for clinically significant prostate cancer.
  • Professor Stricker was the Principal Supervisor for this thesis and will continue to be the Principal Supervisor for Dr. Blazevski’s Doctor of Philosophy (Phd) Urology commencing in 2019.
• Professor Stricker was the first robotic surgeon in New South Wales and the third in Australia to successfully complete 2,000 robotic radical prostatectomies. He has paid tribute to the outstanding team of nurses, assistants and anesthetists at St Vincent’s, emphasizing how critical they have been to the success of the program at this hospital.
• Abstract with title ‘3-year outcomes from the prospective ‘MRIAS’ trial: A novel active surveillance protocol which incorporates multiparametric MRI to reduce frequency of biopsy in men with prostate cancer’ has been selected as one of the ‘Best EAU22 abstracts’ by the Scientific Committee 24 Jun 2022.
• Awarded the ‘Best Scientific Paper’ published in European Urology in 2021. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
• Recipient of the Alavi–Mandell Award (May 2023) for publication “Robot-Assisted Prostate-Specific Membrane Antigen–Radioguided Surgery in Primary Diagnosed Prostate Cancer”.

Significant Publications

Focal Therapy

Valerio, M., P. D. Stricker, H. U. Ahmed, L. Dickinson, L. Ponsky, R. Shnier, C. Allen, and M. Emberton. 2014. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis, 17: 343 https://doi.org/10.1038/pcan.2014.33″

Ting, F., M. Tran, M. Böhm, A. Siriwardana, P. J. Van Leeuwen, A. M. Haynes, W. Delprado, R. Shnier, and P. D. Stricker. 2015. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer And Prostatic Diseases, 19: 46. https://doi.org/10.1038/pcan.2015.47″

Ting, F., P. J. Van Leeuwen, and P. D. Stricker. 2016. Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide. J Vasc Interv Radiol, 27: 568 https://doi.org/10.1016/j.jvir.2016.01.003″

Scheltema, M. J., W. van den Bos, A. R. Siriwardana, A. M. F. Kalsbeek, J. E. Thompson, F. Ting, M. Bohm, A. M. Haynes, R. Shnier, W. Delprado, and P. D. Stricker. 2017. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. BJU Int, 120 Suppl 3: 51-58. https://doi.org/10.1111/bju.13991″

Scheltema, M. J., J. I. Chang, M. Bohm, W. van den Bos, A. Blazevski, I. Gielchinsky, A. M. F. Kalsbeek, P. J. van Leeuwen, T. V. Nguyen, T. M. de Reijke, A. R. Siriwardana, J. E. Thompson, J. J. de la Rosette, and P. D. Stricker. 2018. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World J Urol. https://doi.org/10.1007/s00345-018-2281-z”

Van den Bos, W., M. J. Scheltema, A. R. Siriwardana, A. M. F. Kalsbeek, J. E. Thompson, F. Ting, M. Bohm, A. M. Haynes, R. Shnier, W. Delprado, and P. D. Stricker. 2018. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int, 121: 716-24. https://doi.org/10.1111/bju.13983″

Scheltema, M. J., J. I. Chang, W. van den Bos, I. Gielchinsky, T. V. Nguyen, T. M. Reijke, A. R. Siriwardana, M. Bohm, J. J. de la Rosette, and P. D. Stricker. 2018. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagn Interv Radiol, 24: 268-75. https://doi.org/10.5152/dir.2018.17374″

Scheltema, M. J., T. J. O’Brien, W. van den Bos, D. M. de Bruin, R. V. Davalos, C. W. M. van den Geld, M. P. Laguna, R. E. Neal, 2nd, I. M. Varkarakis, A. Skolarikos, P. D. Stricker, T. M. de Reijke, C. B. Arena and J. de la Rosette (2019). umerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences. Ther Adv Urol 11: 1756287219852305. https://doi.org/10.1177/1756287219852305″

Blazevski, A., M. J. Scheltema, A. Amin, J. E. Thompson, N. Lawrentschuk and P. D. Stricker (2019). rreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int, https://doi.org/10.1111/bju.14951″

Blazevski A., M. J. Scheltema, B. Yuen, N. Masand, T. V. Nguyen, W.Delprado, R. Shnier, A. Haynes, T. Cusick, J. Thompson, P. Stricker. ncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. Eur Urol. Oncol(2019). https://doi.org/10.1016/j.euo.2019.04.008″

Blazevski, A., M. J. Scheltema, A. Amin, J. E. Thompson, N. Lawrentschuk and P. D. Stricker (2020). Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int 125(3): 369-378. https://doi.org/10.1111/bju.14951″

Blazevski A, Amin A, Scheltema MJ, Balakrishnan A, Haynes AM, Barreto D, Cusick T, Thompson J, Stricker PD. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). World J Urol. 2021 Apr;39(4):1107-1114. https://doi.org/10.1007/s00345-020-03275-z”  Epub 2020 Jun 2.

Cussenot O, Stricker PD. Irreversible electroporation for patients with localised prostate cancer: Expert opinion on this versatile therapeutic approach. EMJ Urol. 2021 Aug:9[1]:56-62.

Blazevski A, Gondoputro W, Scheltema MJ, Amin A, Geboers B, Barreto D, Haynes AM, Shnier R, Delprado W, Agrawal S, Thompson JE, Stricker PD. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes. BMC Urol. 2022 Mar 2;22(1):28. https://doi.org/10.1186/s12894-022-00978-w”.

Geboers B, Gondoputro W, Thompson JE, Reesink DJ, van Riel LAMJG, Zhang D, Blazevski A, Doan P, Agrawal S, Matthews J, Haynes AM, Liu Z, Delprado W, Shnier R, de Reijke TM, Lawrentschuk N, Stijns PEF, Yaxley JW, Scheltema MJ, Stricker PD. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study.Eur Urol Focus. 2022 May 13:S2405-4569(22)00106-7. https://doi.org/10.1016/j.euf.2022.04.010″. Epub ahead of print.

van Riel LAMJG, Geboers B, Kabaktepe E, Blazevski A, Reesink DJ, Stijns P, Stricker PD, Casanova J, Dominguez-Escrig JL, de Reijke TM, Scheltema MJ, Oddens JR. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. BJU Int. 2022 Apr 27. https://doi.org/10.1111/bju.15759″. Epub ahead of print.

Ong S, Chen K, Grummet J, Yaxley J, Scheltema MJ, Stricker P, Tay KJ, Lawrentschuk N. Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus? BJU Int. 2022 Sep 9. https://doi.org/10.1111/bju.15883″. Epub 2022 Sep 27. PMID: 36083229.

Emberton M, Reijke T;, Stricker P, Miñana, Bianco F, Dominguez Escrig J, Lantz A, Sanchez-Salas R. Revisiting Delphi to create a basis for the future of focal therapy for prostate cancer. Urology Journal URL-D-23-00730

Lantz A, Nordlund P, Falagario U, Jäderling F, Özbek O, Clements M, Discacciati A, Grönberg H, Eklund M, Stricker P, Emberton M, Aly M, Nordström T. Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. Eur Urol Open Sci. 2023 Apr 8;51:89-94. https://doi.org/10.1016/j.euros.2023.03.003″. PMID: 37091033; PMCID: PMC10114162.

Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ; Focal Therapy Society. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol, 2023 Jul 5:S0302-2838(23)02943-3. https://doi.org/10.1016/j.eururo.2023.06.013″. Epub ahead of print. PMID: 37419773.

Scheltema MJ, Katelaris A, Stricker PD. Salvage irreversible electroporation for radio-recurrent prostate cancer. Nat Rev Urol. 2023 Mar 1. https://doi.org/10.1038/s41585-023-00750-1″. Epub ahead of print. PMID: 36859611.

Rodríguez-Sánchez L, Emberton M, de Reijke T, Stricker P, Miñana B, Bianco F, Escrig JLD, Lantz A, Sanchez-Salas R. Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer. World J Mens Health. 2023 Oct 16. DOI: 10.5534/wjmh.230160. Epub ahead of print. PMID: 37853538.

Zhang K, Stricker P, Löhr M, Stehling M, Suberville M, Cussenot O, Lunelli L, Ng CF, Teoh J, Laguna P, de la Rosette J. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer.  Prostate cancer and prostatic diseases. 2024 Jan 9. https://doi.org/10.1038/s41391-023-00783-y”. Epub ahead of print. PMID: 38195916.

Active Surveillance

Thompson, J. E., A. Hayen, A. Landau, A. M. Haynes, A. Kalapara, J. Ischia, J. Matthews, M. Frydenberg, and P. D. Stricker. 2015. Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. BJU Int, 115: 884-91. https://doi.org/10.1111/bju.12858″

Bayliss, D., J. Duff, P. Stricker, and K. Walker. 2016. Decision-Making in Prostate Cancer: Active Surveillance Over Other Treatment Options. Urol Nurs, 36: 141-9.

Galvao, D. A., D. R. Taaffe, N. Spry, R. A. Gardiner, R. Taylor, G. P. Risbridger, M. Frydenberg, M. Hill, S. K. Chambers, P. Stricker, T. Shannon, D. Hayne, E. Zopf, and R. U. Newton. 2016. Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nat Rev Urol, 13: 258-65. https://doi.org/10.1038/nrurol.2016.46″

Amin, A., M. J. Scheltema, R. Shnier, A. Blazevski, D. Moses, T. Cusick, A. Siriwardena, B. Yuen, P. J. v. Leeuwen, A. M. Haynes, J. Matthews, P. Brenner, G. O’Neill, C. Yuen, W. Delprado, P. Stricker and J. Thompson (2020) “The MRI in Active Surveillance (MRIAS); Trial: Use of Baseline mpMRI and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies. Journal of Urology, 203(5), 910-17 10.1097/JU.0000000000000693

Cooperberg MR, Zheng Y, Faino AV, et al. Tailoring intensity of Active surveillance for low-risk prostate cancer based on online August 27, 2020. DOI: 10.1001/jamaoncol.2020.3187

Watson V, McCartan N, Krucien N, Abu V, Ikenwilo D, Emberton M, Ahmed HU. Evaluating the Trade-offs Men with Localized Prostate Cancer Make between the Risks and Benefits of Treatments: The COMPARE Study. The Journal of Urology, 2020 Jan 22:10-97. https://doi.org/10.1097/JU.0000000000000754″

Beckmann K, Santaolalla A, Helleman J, Carroll P, Ha Chung B, Shiong Lee L, Perry A, Rubio-Briones J, Sugimoto M, Trock B, Valdagni R, Dasgupta P, Van Hemelrijck M, Elhage O; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. Eur Urol Open Sci. 2021 Nov 1;34:47-54. https://doi.org/10.1016/j.euros.2021.09.012″. PMID: 34934967; PMCID: PMC8655390.

Olivier J, Li W, Nieboer D, Helleman J, Roobol M, Gnanapragasam V, Frydenberg M, Sugimoto M, Carroll P, Morgan TM, Valdagni R, Rubio-Briones J, Robert G, Stricker P, Hayen A, Schoots I, Haider M, Moore CM, Denton B, Villers A; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium. Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Eur Urol Open Sci. 2022 Jan 3;35:59-67. https://doi.org/10.1016/j.euros.2021.11.006″. PMID: 35024633; PMCID: PMC8738894.

Beckmann KR, Bangma CH, Helleman J, Bjartell A, Carroll PR, Morgan T, Nieboer D, Santaolalla A, Trock BJ, Valdagni R, Roobol MJ; Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate. 2022 May;82(7):876-879. https://doi.org/10.1002/pros.24330″. Epub 2022 Mar 7. PMID: 35254666; PMCID: PMC9541488.

Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, Sugimoto M, Ehdaie B, Morgan TM, Rubio-Briones J, Semjonow A, Bangma CH, Roobol MJ; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. Eur Urol Open Sci. 2022 Jun 14;41:126-133. https://doi.org/10.1016/j.euros.2022.05.012″. PMID: 35813247; PMCID: PMC9257656.

Marenghi C, Qiu Z, Helleman J, Nieboer D, Rubio-Briones J, Carroll PR, Lee LS, Valdagni R, Boutros PC, Nicolai N; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort. Cancers (Basel). 2022 Jul 22;14(15):3558. https://doi.org/10.3390/cancers14153558″. PMID: 35892817; PMCID: PMC9332009.

Doan P, Scheltema MJ, Amin A, Shnier R, Geboers B, Gondoputro W, Moses D, van Leeuwen PJ, Haynes AM, Matthews J, Brenner P, O’Neill G, Yuen C, Delprado W, Stricker P, Thompson J. Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial. J Urol, 2022 Nov;208(5):1028-1036. https://doi.org” 02885. Epub 2022 Aug 10. PMID: 35947521.

68Ga-PSMA PET/CT in addition to mpMRI in men undergoing biopsy during Active Surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study

Imaging

Thompson, J., N. Lawrentschuk, M. Frydenberg, L. Thompson, and P. Stricker. 2013. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int, 112 Suppl 2: 6-20. https://doi.org/10.1111/bju.12381″

Thompson, J. E., D. Moses, R. Shnier, P. Brenner, W. Delprado, L. Ponsky, M. Pulbrook, M. Bohm, A. M. Haynes, A. Hayen, and P. D. Stricker. 2014. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol, 192: 67-74. https://doi.org/10.1016/j.juro.2014.01.014″

Morigi, J. J., P. D. Stricker, P. J. van Leeuwen, R. Tang, B. Ho, Q. Nguyen, G. Hruby, G. Fogarty, R. Jagavkar, A. Kneebone, A. Hickey, S. Fanti, L. Tarlinton, and L. Emmett. 2015. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med, 56: 1185-90. https://doi.org/10.2967/jnumed.115.160382″

van Leeuwen, P. J., P. Stricker, G. Hruby, A. Kneebone, F. Ting, B. Thompson, Q. Nguyen, B. Ho, and L. Emmett. 2016. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int, 117: 732-9. https://doi.org/10.1111/bju.13397″

Emmett, L., P. J. van Leeuwen, R. Nandurkar, M. J. Scheltema, T. Cusick, G. Hruby, A. Kneebone, T. Eade, G. Fogarty, R. Jagavkar, Q. Nguyen, B. Ho, A. M. Joshua, and P. Stricker. 2017. Treatment Outcomes from (68)Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. J Nucl Med, 58: 1972-76. https://doi.org/10.2967/jnumed.117.196683″

Ginsburg, S. B., A. Algohary, S. Pahwa, V. Gulani, L. Ponsky, H. J. Aronen, P. J. Bostrom, M. Bohm, A. M. Haynes, P. Brenner, W. Delprado, J. Thompson, M. Pulbrock, P. Taimen, R. Villani, P. Stricker, A. R. Rastinehad, I. Jambor, and A. Madabhushi. 2017. Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study. J Magn Reson Imaging. 2017 Jul;46(1):184-193. https://doi.org/10.1002/jmri.25562″

Thompson, J. E., P. J. van Leeuwen, D. Moses, R. Shnier, P. Brenner, W. Delprado, M. Pulbrook, M. Bohm, A. M. Haynes, A. Hayen, and P. D. Stricker. 2016. The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer. J Urol, 195: 1428-35. https://doi.org/10.1016/j.juro.2015.10.140″

Ting, F., P. J. Van Leeuwen, J. Thompson, R. Shnier, D. Moses, W. Delprado, and P. D. Stricker. 2016. Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy. Prostate Cancer, 2016: 3794738. https://doi.org/10.1155/2016/3794738″

Tran, M., J. Thompson, M. Böhm, M. Pulbrook, D. Moses, R. Shnier, P. Brenner, W. Delprado, AM. Haynes, R. Savdie, and P. Stricker. 2016. Combination of multiparametric MRI and transperineal template‐guided mapping biopsy of the prostate to identify candidates for hemi‐ablative focal therapy. BJU International, 117: 48-54. https://doi.org/10.1111/bju.13090″

Rusu, M., A. S. Purysko, S.Verma, J. Kiechle, J.Gollamudi, S. Ghose, K.Herrmann, V. Gulani, R. Paspulati, L. Ponsky, M. Böhm, A.M. Haynes, D. Moses, R. Shnier, W. Delprado, J. Thompson, P. Stricker, and A. Madabhushi. 2017. Computational imaging reveals shape differences between normal and malignant prostates on MRI. Scientific Reports, 7: 41261. doi:  doi.org/10.1038/srep41261

Scheltema, M. J., J. I. Chang, W. van den Bos, M. Bohm, W. Delprado, I. Gielchinsky, T. M. de Reijke, J. J. de la Rosette, A. R. Siriwardana, R. Shnier, and P. D. Stricker. 2017. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation. Eur Urol Focus. https://doi.org/10.1016/j.euf.2017.10.007″

Siriwardana, A., J. Thompson, P. J. van Leeuwen, S. Doig, A. Kalsbeek, L. Emmett, W. Delprado, D. Wong, H. Samaratunga, A. M. Haynes, G. Coughlin, and P. Stricker. 2017. Initial multicentre experience of (68) gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU Int, 120: 673-81. https://doi.org/10.1111/bju.13919″

Siriwardana, A., W van den Bos, J. Thompson, R. Shnier, and P.D. Stricker. 2017. The role of MRI in prostate cancer: A changing paradigm. MedicineToday, 18.

Thompson, J., and P. Stricker. 2017. MRI improves cost and accuracy of prostate cancer biopsy. Nature Reviews Urology, 15: 6. https://doi.org/10.1038/nrurol.2017.185″

Thompson, J. E., and P. D. Stricker. 2017. Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. Lancet, 389: 767-68. https://doi.org/10.1016/s0140-6736(17)30121-6″

van Leeuwen, P. J., L. Emmett, B. Ho, W. Delprado, F. Ting, Q. Nguyen, and P. D. Stricker. 2017. Prospective evaluation of 68Gallium- prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int, 119: 209-15. https://doi.org/10.1111/bju.13540″

van Leeuwen, P. J., A. Hayen, J. E. Thompson, D. Moses, R. Shnier, M. Bohm, M. Abuodha, A. M. Haynes, F. Ting, J. Barentsz, M. Roobol, J. Vass, K. Rasiah, W. Delprado, and P. D. Stricker. 2017. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int, 120: 774-81. doi:  doi.org/10.1111/bju.13814

Algohary, A., S. Viswanath, R. Shiradkar, S. Ghose, S. Pahwa, D. Moses, I. Jambor, R. Shnier, M. Bohm, A. M. Haynes, P. Brenner, W. Delprado, J. Thompson, M. Pulbrock, A. S. Purysko, S. Verma, L. Ponsky, P. Stricker, and A. Madabhushi. 2018. Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings. J Magn Reson Imaging. https://doi.org/10.1002/jmri.25983″

Emmett, L., R. Nandurkar, P. Van Leeuwen, H. Woo, R. Kooner, D. Ende, G. O’Neill, C. Yuen, B. Ho, Q. Nguyen, A. Hickey, and P. Stricker. 2018. Staging with Ga-68 HBED-CC-Glu-NH-CO-NH-Lys (Ahx) PSMA-11 PET CT (PSMA) prior to radical prostatectomy has high predictive value in assessing biochemical response to surgery. European Urology Supplements, 17: e1903. https://doi.org/10.1016/S1569-9056(18)32310-8″

Roach, P. J., R. Francis, L. Emmett, E. Hsiao, A. Kneebone, G. Hruby, T. Eade, Q. A. Nguyen, B. D. Thompson, T. Cusick, M. McCarthy, C. Tang, B. Ho, P. D. Stricker, and A. M. Scott. 2018. The Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med, 59: 82-88. https://doi.org/10.2967/jnumed.117.197160″

Gielchinsky, I., M. J. Scheltema, T. Cusick, J. Chang, R. Shnier, D. Moses, W. Delprado, Q. Nguyen, C. Yuen, A. M. Haynes, and P. D. Stricker. 2018. Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50. Res Rep Urol, 10: https://doi.org/10.2147/RRU.S169017

Penzias, G., A. Singanamalli, R. Elliott, J. Gollamudi, N. Shih, M. Feldman, P. D. Stricker, W. Delprado, S. Tiwari, M. Bohm, A. M. Haynes, L. Ponsky, P. Fu, P. Tiwari, S. Viswanath, and A. Madabhushi. 2018. Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings. PLoS One, 13: e0200730. https://doi.org/10.1371/journal.pone.0200730″

Thompson, J. E., and P. D. Stricker. 2018. MRI improves active surveillance of prostate cancer however biopsy is still crucial. BJU Int, 122: E1-E2. https://doi.org/10.1111/bju.14424″

Emmett, L., M. Crumbaker, B. Ho, K. Willowson, P. Eu, L. Ratnayake, R. Epstein, A. Blanksby, L. Horvath, A. Guminski, K. Mahon, C. Gedye, C. Yin, P. Stricker and A. M. Joshua (2019). esults of a Prospective Phase 2 Pilot Trial of (177)Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. Clin Genitourin Cancer 17(1): 15-22. https://doi.org/10.1016/j.clgc.2018.09.014″

Van Leeuwen, P. J., L. Emmett, M. L. Donswijk, P. D. Stricker, F. J. Pos, E. M. K. Wit and H. G. van der Poel (2019). ‘Early outcomes after [68Ga]PSMA-PET/CT guided salvage therapy in men with biochemical recurrence after radical prostatectomy | [Vroege oncologische uitkomsten van [68Ga]PSMA-PET/CT-gestuurde salvagetherapie bij mannen met biochemisch recidief na radicale prostatectomie] Tijdschrift voor Urologie 9(1): 2-8. https://doi.org/10.1007/s13629-018-00215-w”

Nandurkar, R., P. van Leeuwen, P. Stricker, H. Woo, R. Kooner, C. Yuen, G. O’Neill, D. Ende, T. Cusick, B. Ho, A. Hickey and L. Emmett (2019). 68)Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery. Br J Radiol 92(1095): 20180667. https://doi.org/10.1259/bjr.20180667″

Scheltema, M. J., J. I. Chang, P. D. Stricker, P. J. van Leeuwen, Q. A. Nguyen, B. Ho, W. Delprado, J. Lee, J. E. Thompson, T. Cusick, A. S. Spriensma, A. R. Siriwardana, C. Yuen, R. Kooner, G. Hruby, G. O’Neill and L. Emmett (2019). iagnostic accuracy of (68) Ga- prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole- mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI. BJU Int, https://doi.org/10.1111/bju.14794″

Emmett, L., R. Tang, R. H. Nandurkar, G. Hruby, P. J. Roach, J. A. Watts, T. Cusick, A. Kneebone, B. Ho, L. Chan, P. van Leeuwen, M. Scheltema, A. Nguyen, C. Yin, A. Scott, C. Tang, M. McCarthy, K. Fullard, M. Roberts, R. Francis and P. Stricker (2019). -year freedom from progression following (68)GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi-center trial. J Nucl Med. https://doi.org/10.2967/jnumed.119.235028″

Algohary, A., R. Shiradkar, S. Pahwa, A. Purysko, S. Verma, D. Moses, R. Shnier, A. M. Haynes, W. Delprado, J. Thompson, S. Tirumani, A. Mahran, A. R. Rastinehad, L. Ponsky, P. D. Stricker and A. Madabhushi (2020). ombination of Peri-Tumoral and Intra- Tumoral Radiomic Features on Bi-Parametric MRI Accurately Stratifies Prostate Cancer Risk: A Multi-Site Study. Cancers (Basel) 12(8). https://doi.org.au/10.3390/cancers12082200″

Louise Emmett, James Buteau, Nathan Papa, Daniel Moon, James Thompson, Matthew Roberts, Kris Rasiah, David Pattison, John Yaxley, Paul Thomas, Anthony Hutton, Shikha Agrawal, Amer Amin, Alexandar Blazevski, Venu Chalasani, Bao Ho, Andrew Nguyen, Victor Liu, Jonathan Lee, Gemma Sheehan-Dare, Raji Kooner, Geoff Coughlin, Lyn Chan, Thomas Cusick, Benjamin Namdarian, Jada Kapoor, Omar Alghazo, Henry Woo, Nathan Lawrentschuk, Declan Murphy, Michael Hofman, Phillip Stricker. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography To Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 2021.ISSN 0302-2838. https://doi.org/10.1016/j.eururo.2021.08.002″

Louise M Emmett, Nathan Papa, James Buteau, Bao Ho, Victor Liu, Matthew Roberts, James Thompson, Daniel Moon, Gemma Sheehan-Dare, Omar Alghazo, Shikha Agrawal, Declan G. Murphy, Phillip Stricker, Thomas A. Hope and Michael Hofman. The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. Journal of Nuclear Medicine March 2022, jnumed.121.263448; https://doi.org/10.2967/jnumed.121.263448

Roberts MJ, Chatfield MD, Hruby G, Nandurkar R, Roach P, Watts JA, Cusick T, Kneebone A, Eade T, Ho B, Nguyen A, Tang C, McCarthy M, Francis R, Stricker P, Emmett L. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups. BJU Int, 2022 Nov;130 Suppl 3(Suppl 3):32-39. doi: 10.1111/bju.15762. Epub 2022 Jul 12. PMID: 35488182; PMCID: PMC9796546. https://doi.org/10.1111/bju.15762″

Ptasznik G, Papa N, Kelly BD, Thompson J, Stricker P, Roberts MJ, Hofman M, Buteau J, Murphy DG, Emmett L, Moon D. High PSMA PET SUVmax in PI‐RADS 4 or 5 men confers a high probability of significant prostate cancer. BJU International, 2022 Apr 1. https://doi.org/10.1111/bju.15736″

Doan P, Counter W, Papa N, Sheehan-Dare G, Ho B, Lee J, Liu V, Thompson JE, Agrawal S, Roberts MJ, Buteau J, Hofman MS, Moon D, Lawrentschuk N, Murphy D, Stricker PD, Emmett L. Synchronous versus independent reading of PSMA-PET and MRI to improve diagnosis for prostate cancer. BJU Int, 2022 Nov 13. https://doi.org/bju.15736″. Epub ahead of print. PMID: 36371669. https://pubmed.ncbi.nlm.nih.gov/36371669/

Vis AN, Meijer D, Roberts MJ, Siriwardana AR, Morton A, Yaxley JW, Samaratunga H, Emmett L, van de Ven PM, Heymans MW, Nieuwenhuijzen JA, van der Poel HG, Donswijk ML, Boellaard TN, Schoots IG, Stricker P, Haynes AM, Oprea-Lager DE, Coughlin GD, van Leeuwen PJ. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol, 2023 Apr 10:S2588-9311(23)00075-5. doi: 10.1016/j.euo.2023.03.010. Epub ahead of print. PMID: 37045707.
Kelly B, Ptasznik G, Roberts MJ, Doan P, Stricker P, Thompson J, Buteau J, Chen K, Alghazo O, O’Brien JS, Hofman MS, Frydenberg M, Lawrentschuk N, Lundon D, Murphy DG, Emmett L and Moon D. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy, European Urology Open Science, 2023. https://doi.org/10.1016/j.euros.2023.05.002″

Samaneh Azargoshasb, Hilda A. de Barros, Daphne D.D. Rietbergen, Paolo Dell’Oglio, Pim J. van Leeuwen, Christian Wagner, Phillip Stricker, Sergi Vidal-Sicart, Alberto Briganti, Tobias Maurer, Henk G. van der Poel, Matthias N. van Oosterom, Fijs W. B. van Leeuwen. Artificial Intelligence-Supported Video Analysis as a Means to Assess the Impact of DROP-IN Image Guidance on Robotic Surgeons: Radioguided Sentinel Lymph Node versus PSMA-Targeted Prostate Cancer Surgery. Advanced Intelligent Systems journal. 2023. https://doi.org/10.1002/aisy.202300192″

Li L, Shiradkar R, Tirumani SH, Bittencourt LK, Fu P, Mahran A, Buzzy C, Stricker PD, Rastinehad AR, Magi-Galluzzi C, Ponsky L, Klein E, Purysko AS, Madabhushi A. Novel radiomic analysis on bi-parametric MRI for characterizing differences between MR non-visible and visible clinically significant prostate cancer. Eur J Radiol Open, 2023 Jun 13;10:100496. https://doi.org/10.1016/j.ejro.2023.100496″. PMID: 37396490; PMCID: PMC10311200.

Radical Prostatectomy/Robotic Surgery

Ricciardelli, C., D. I. Quinn, W. A. Raymond, K. McCaul, P. D. Sutherland, P. D. Stricker, J. J. Grygiel, R. L. Sutherland, V. R. Marshall, W. D. Tilley, and D. J. Horsfall. 1999. ‘Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res, 59: 2324-8.

Quinn, D. I., S. M. Henshall, D. R. Head, D. Golovsky, J. D. Wilson, P. C. Brenner, J. J. Turner, W. Delprado, J. F. Finlayson, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2000. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res, 60: 1585-94.

Quinn, D. I., S.M. Henshall, A.M. Haynes, P. C. Brenner, R. Kooner, D. Golovsky, J. Mathews, G. F. O’Neill, J. J. Turner, W. Delprado, J. F. Finlayson, R. L. Sutherland, J. J. Grygiel, and P. D. Stricker. 2001. Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models. Journal of Clinical Oncology, 19: 3692-705. https://doi.org/10.1200/jco.2001.19.16.3692″

Graefen, M., P. I. Karakiewicz, I. Cagiannos, E. Klein, P. A. Kupelian, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, J. de Kernion, T. Cangiano, F. H. Schroder, M. F. Wildhagen, P. T. Scardino, and M. W. Kattan. 2002. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol, 20: 951-6. https://doi.org/10.1200/jco.2002.20.4.951″

Graefen, M., P. I. Karakiewicz, I. Cagiannos, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, E. Klein, P. Kupelian, D. G. Skinner, G. Lieskovsky, B. Bochner, H. Huland, P. G. Hammerer, A. Haese, A. Erbersdobler, J. A. Eastham, J. de Kernion, T. Cangiano, F. H. Schroder, M. F. Wildhagen, T. H. van der Kwast, P. T. Scardino, and M. W. Kattan. 2002. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol, 20: 3206-12. https://doi.org/10.1200/jco.2002.12.019″

Quinn, D. I., S. M. Henshall, P. C. Brenner, R. Kooner, D. Golovsky, G. F. O’Neill, J. J. Turner, W. Delprado, J. J. Grygiel, R. L. Sutherland, and P. D. Stricker. 2003. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer, 97: 1884-93. https://doi.org/10.1002/cncr.11263″

Stricker, P., J Matthews, and A. M. Haynes. 2004. Radical Prostatectomy: A personal series of 700 cases over 14 years: Evolution in technique. ANZ Journal of Surgery, 74: A1-A8.

Cagiannos, I., P. Karakiewicz, M. Graefen, J. A. Eastham, M. Ohori, F. Rabbani, V. Reuter, T. Wheeler, P. Kupelian, E. Klein, H. Huland, P. G. Hammerer, A. Erbersdobler, F. Schroeder, M. Wildhagen, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, C. G. Morash, P. T. Scardino, and M. W. Kattan. 2004. Is year of radical prostatectomy a predictor of outcome in prostate cancer?. J Urol, 171: 692-6. https://doi.org/10.1097/01.ju.0000107260.98031.0e”

Montorsi, F., P. Stricker, E. Jaudinot, C. Wohlhuter, P. Puppo, and P. Teillac. 2004. Stratification by outcomes affecting response to Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy. European Urology Supplements, 3: 32. https://doi.org/10.1016/S1569-9056(04)90121-2″

Teillac, P., P. Stricker, E. Jaudinot, C. Wohlhuter, and F. Montorsi. 2004. Efficacy and safety of Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy. European Urology Supplements, 3: 33. https://doi.org/10.1016/S1569-9056(04)90124-8″

Henshall, S. M., L. G. Horvath, D. I. Quinn, S. A. Eggleton, J. J. Grygiel, P. D. Stricker, A. V. Biankin, J. G. Kench, and R. L. Sutherland. 2006. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst, 98: 1420-4. https://doi.org/10.1093/jnci/djj378″

Macek, P, P. Stricker, M. Stevens, R. Jagavkar, V. Chalasani, A.M. Haynes, J Mathews, P. Brenner, D. Golovsky, R Kooner, and F. O’Neill G. 2006. Outcomes of radical prostatectomies and HDR brachytherapy in patients with intermediate and high risk prostate cancer. BJU International, 97: 3-3. https://doi.org/10.1111/j.1464-410X.2006.06085_12.x”

Padma-Nathan, H., A. R. McCullough, L. A. Levine, L. I. Lipshultz, R. Siegel, F. Montorsi, F. Giuliano, and G. Brock. 2008. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res, 20: 479-86. https://doi.org/10.1038/ijir.2008.33″

Stricker, P. 2008. Ethical Introduction to Robotic Radical Prostatectomy Surgery for an Experienced Open Surgeon. Journal of Robotic Surgery, 2: 105-33.

Stricker, P. 2008. Approaches to Nerve Sparing Retrograde Athermal Technique. Journal of Robotic Surgery, 2: 105-33.

Chen, P., R. Thanigasalam, P. Stricker, J Mathews, R. DeBenito, A. M. Haynes, S. M. Henshall, and K. K. Rasiah. 2009. The Clinico- Pathological Outcome of Men Undergoing Prostatectomy with PSA < 4. BJUI International, 103: 1-48. https://doi.org/10.1111/j.1464-410X.2009.09021.x”

Chen, P., R. Thanigasalm, S. M. Henshall, A. M. Haynes, J Mathews, and P. Stricker. 2009. Prospective Comparative Analysis of Clinico-Pathological Outcomes Between Robotic Assisted and Open Radical Prostatectomy. BJUI International, 103: 1-48. https://doi.org/10.1111/j.1464-410X.2009.09021.x”

Doumerc, N., C. Yuen, R. Savdie, M. B. Rahman, R. Pe Benito, and P. Stricker. 2010. Robot-assisted laparoscopic prostatectomy: analysis of an experienced open surgeon’s learning curve after 300 procedures. J Robot Surg, 3: 229-34. https://doi.org/10.1007/s11701-010-0171-5″

Doumerc, N., C. Yuen, R. Savdie, M. B. Rahman, K. K. Rasiah, R. Pe Benito, W. Delprado, J. Matthews, A. M. Haynes, and P. D. Stricker. 2010. Should experienced open prostatic surgeons convert to robotic surgery? The real learning curve for one surgeon over 3 years. BJU Int, 106: 378-84. https://doi.org/10.1111/j.1464-410X.2009.09158.x”

Moore, B., R. DeBenito, A. M. Haynes, and P. Stricker. 2010. The Impact of Nerve Sparing Surgical Margins Status and Oncological Outcome in Radical Prostatectomy. BJU International Authours Journal Compliation, 105: 1-38. https://doi.org/10.1111/j.1464-410X.2010.09122.x”

Talantov, D., T. A. Jatkoe, M. Bohm, Y. Zhang, A. M. Ferguson, P. D. Stricker, M. W. Kattan, R. L. Sutherland, J. G. Kench, Y. Wang, and S. M. Henshall. 2010. Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy. J Urol, 184: 1521-8. https://doi.org/10.1016/j.juro.2010.05.084″

Thanigasalam, R., K. K. Rasiah, P. D. Stricker, A. M. Haynes, S. I. Sutherland, R. L. Sutherland, S. M. Henshall, and L. G. Horvath. 2010. Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. BJU Int, 105: 642-7. https://doi.org/10.1111/j.1464-410X.2009.08842.x”

Hossack, T., M. I. Patel, A. Huo, P. Brenner, C. Yuen, D. Spernat, J. Mathews, A. M. Haynes, R. Sutherland, W. del Prado, and P. Stricker. 2012. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. J Urol, 188: 781-5. https://doi.org/10.1016/j.juro.2012.05.006″

Huo, A. S., T. Hossack, J. L. Symons, R. PeBenito, W. J. Delprado, P. Brenner, and P. D. Stricker. 2012. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. J Urol, 187: 2044-9. https://doi.org/10.1016/j.juro.2012.01.066″

Moore, B. M., R. Savdie, R. A. PeBenito, A. M. Haynes, J. Matthews, W. Delprado, K. K. Rasiah, and P. D. Stricker. 2012. The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy. BJU Int, 109: 533-8. https://doi.org/10.1111/j.1464-410X.2011.10361.x”

Savdie, R., L. G. Horvath, R. P. Benito, K. K. Rasiah, A. M. Haynes, M. Chatfield, P. D. Stricker, J. J. Turner, W. Delprado, S. M. Henshall, R. L. Sutherland, and J. G. Kench. 2012. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int, 109: 1794-800. https://doi.org/10.1111/j.1464-410X.2011.10572.x”

Savdie, R., J. Symons, D. Spernat, C. Yuen, R. A. Pe Benito, A. M. Haynes, J. Matthews, K. K. Rasiah, R. S. Jagavkar, C. Yu, G. Fogarty, M. W. Kattan, P. Brenner, R. L. Sutherland, and P. D. Stricker. 2012. High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse. BJU Int, 110 Suppl 4: 71-6. https://doi.org/10.1111/j.1464-410X.2012.11480.x”

Beattie, K., J. Symons, S. Chopra, C. Yuen, R. Savdie, R. Thanigasalam, A. M. Haynes, J. Matthews, P. C. Brenner, K. Rasiah, R. L. Sutherland, and P. D. Stricker. 2013. A novel method of bladder neck imbrication to improve early urinary continence following robotic-assisted radical prostatectomy. Journal of Robotic Surgery, 7: 193-99. https://doi.org/10.1007/s11701-012-0371-2″

Sooriakumaran, P., A. Srivastava, S. F. Shariat, P. D. Stricker, T. Ahlering, C. G. Eden, P. N. Wiklund, R. Sanchez-Salas, A. Mottrie, D. Lee, D. E. Neal, R. Ghavamian, P. Nyirady, A. Nilsson, S. Carlsson, E. Xylinas, W. Loidl, C. Seitz, P. Schramek, C. Roehrborn, X. Cathelineau, D. Skarecky, G. Shaw, A. Warren, W. J. Delprado, M. Haynes, E. Steyerberg, M. J. Roobol, and A. K. Tewari. 2014. A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot- assisted radical prostatectomy patients. Eur Urol, 66: 450-6. https://doi.org/10.1016/j.eururo.2013.11.018″

Thompson, J. E., S. Egger, M. Bohm, A. M. Haynes, J. Matthews, K. Rasiah, and P. D. Stricker. 2014. Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases. Eur Urol, 65: 521-31. https://doi.org/10.1016/j.eururo.2013.10.030″

Grogan, J., R. Gupta, K. L. Mahon, P. D. Stricker, A. M. Haynes, W. Delprado, J. Turner, L. G. Horvath, and J. G. Kench. 2017. Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up. BJU Int, 120: 651-58. https://doi.org/10.1111/bju.13857″

Thompson, J. E., S. Egger, M. Bohm, A. R. Siriwardana, A. M. Haynes, J. Matthews, M. J. Scheltema, and P. D. Stricker. 2018. Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases. Eur Urol, 73: 664-71. https://doi.org/10.1016/j.eururo.2017.11.035″

Zhang, A. Y., K. Chiam, Y. Haupt, S. B. Fox, S. Birch, W.Tilley, L. Butler, K. E. Knudsen, C. Cornstock, K. Rasiah, J. Grogan, K.L. Mahon, T. Bianco-Miotto, M. Bohm, S. M. Henshall, W. Delprado, P. Stricker, L. Horvath, and J. Kench. 2018. An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Journal of Clinical Oncology, 36: 54-54. https://doi.org/10.1200/JCO.2018.36.6_suppl.54″

Zhang, A. Y., K. Chiam, Y. Haupt, S. Fox, S. Birch, W. Tilley, L. M. Butler, K. Knudsen, C. Comstock, K. Rasiah, J. Grogan, K. L. Mahon, T. Bianco-Miotto, C. Ricciardelli, M. Bohm, S. Henshall, W. Delprado, P. Stricker, L. G. Horvath, and J. G. Kench. 2018. An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy. Int J Cancer. https://doi.org/10.1002/ijc.31906″

van Leeuwen, P. J., M. Donswijk, R. Nandurkar, P. Stricker, B. Ho, S. Heijmink, E. M. K. Wit, C. Tillier, E. van Muilenkom, Q. Nguyen, H. G. van der Poel and L. Emmett (2018). 8Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high-risk prostate cancer. BJU Int, https://doi.org/10.1111/bju.14506″

Luiting, H. B., P. J. van Leeuwen, M. B. Busstra, T. Brabander, H. G. van der Poel, M. L. Donswijk, A. N. Vis, L. Emmett, P. D. Stricker and M. J. Roobol (2020). se of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int 125(2): 206-214. https://doi.org/10.1111/bju.14944″

Gondoputro W, Blazevski A, Amin A, Scheltema M, Agrawal S, Cusick T, Van Leeuwen P, Van Leeuwen F, Emmett L, Thompson J, Stricker P. Interim results from the DETECT Trial: A prospective clinical trial evaluating 99MTC-Labelled PSMA Radioguided surgery to aid the intraoperative detection of lymph node metastases during Robot-Assisted Radical Prostatectomy and extended pelvic lymph node dissection for prostate cancer. (Abstract) The Journal of Urology, 2021 Sep;206(Supplement3):e887. https://doi.org/10.1097/JU.0000000000002076.05″

Gondoputro W, Thompson J, Evans M, Bolton D, Frydenberg M, Murphy DG, Haynes AM, Agrawal S, Stricker P, Papa N. How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. The Journal of Urology, 2022 Jan 3:10-97. https://doi.org/10.1097/JU.0000000000002391″

Vis AN, van den Bergh RC, van der Poel HG, Mottrie A, Stricker PD, Graefen M, Patel V, Rocco B, Lissenberg‐Witte B, van Leeuwen PJ. Selection of patients for nerve sparing surgery in robot‐assisted radical prostatectomy. BJUI Compass, 2021. https://doi.org/10.1002/bco2.115″

Gondoputro W, Scheltema MJ, Blazevski A, Doan P, Thompson JE, Amin A, Geboers B, Agrawal S, Siriwardana AR, Van Leeuwen PJ, van Oosterom MN, Leeuwen F, Emmett L, Stricker P. Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer. Journal of Nuclear Medicine. 2022 Mar 1. jnumed.121.263743; https://doi.org/10.2967/jnumed.121.263743

de Barros HA, Remmers S, Luiting HB, van Leenders GJLH, Roobol MJ, Bekers EM, Amin A, Haynes AM, Delprado W, Stricker PD, van der Poel HG, van der Kwast TH, van Leeuwen PJ. Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection. Urology, 2022 Oct;168:156-164. Epub 2022 Jul 5. PMID: 35803346. DOI: 10.1016/j.urology.2022.04.043

Best O, Canagasingham A, Liu Z, Doan P, Haynes AM, Delprado W, Maclean F, Yuen C, Stricker P, Thompson J. Index grade group is superior to composite grade group for prediction of biochemical recurrence following radical prostatectomy. Pathology. 2023 Jan 11:S0031-3025(23)00003-X. doi: 10.1016/j.pathol.2022.10.012. Epub ahead of print. PMID: 36725447

Doan P, Katelaris A, Scheltema MJ, Hayen A, Amin A, Siriwardana A, Tran M, Geboers B, Gondoputro W, Haynes AM, Matthews J, Delprado W, Stricker PD, Thompson J. The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer. BMC Urol. 2023 Apr 28;23(1):68. doi: 10.1186/s12894-023-01228-3. PMID: 37118731; PMCID: PMC10148506.

Hassan, S. P., de Leon, J., Batumalai, V., Moutrie, Z., Hogan, L., Ge, Y., Stricker, P., & Jameson, M. G. (2024). Magnetic resonance guided adaptive post prostatectomy radiotherapy: Accumulated dose comparison of different workflows. Journal of applied clinical medical physics, e14253. Advance online publication. https://doi.org/10.1002/acm2.14253

Radio Therapy

MJ, Stevens, Stricker PD, Saalfeld J, Brenner PC, Kooner R, O’Neill GFA, Duval PJ, Jagavkar RS, Cross P, and Martland J. 2003. Treatment of localized prostate cancer using a combination of high dose rate Iridium‐192 brachytherapy and external beam irradiation: Initial Australian experience. Australasian Radiology, 47: 152-60. https://doi.org/10.1046/j.0004-8461.2003.01143.x” 2003.01143 .x

Stevens, M., P.D. Stricker, J. Saalfeld, P. Brenner, and R Kooner. 2006. Treatment of localised prostate cancer using a combination of high dose‐rate Ir‐192 brachytherapy (HDRB) and external beam radiation therapy (EBRT): a 7 year experience. BJU International, 97: 3-4. https://doi.org/10.1111/j.1464-410X.2006.06085_13.x”

Genomics

Henshall, S. M., D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2001. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res, 61: 423-7.

Henshall, S. M., D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2001. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res, 7: 544-50.

Horvath, L. G., S. M. Henshall, C. S. Lee, D. R. Head, D. I. Quinn, S. Makela, W. Delprado, D. Golovsky, P. C. Brenner, G. O’Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, J. A. Gustafsson, and R. L. Sutherland. 2001. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res, 61: 5331-5.

Henshall, S. M., D. E. Afar, J. Hiller, L. G. Horvath, D. I. Quinn, K. K. Rasiah, K. Gish, D. Willhite, J. G. Kench, M. Gardiner-Garden, P. D. Stricker, H. I. Scher, J. J. Grygiel, D. B. Agus, D. H. Mack, and R. L. Sutherland. 2003. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res, 63: 4196-203.

Henshall, S. M., D. E. Afar, K. K. Rasiah, L. G. Horvath, K. Gish, I. Caras, V. Ramakrishnan, M. Wong, U. Jeffry, J. G. Kench, D. I. Quinn, J. J. Turner, W. Delprado, C. S. Lee, D. Golovsky, P. C. Brenner, G. F. O’Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, D. H. Mack, and R. L. Sutherland. 2003. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene, 22: 6005-12. https://doi.org/10.1038/sj.onc.1206797″

Afar, D. E., V. Bhaskar, E. Ibsen, D. Breinberg, S. M. Henshall, J. G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, C. O’Hara, D. Powers, R. B. DuBridge, I. Caras, R. Winter, T. Anderson, N. Solvason, P. D. Stricker, C. Cordon-Cardo, H. I. Scher, J. J. Grygiel, R. L. Sutherland, R. Murray, V. Ramakrishnan, and D. A. Law. 2004. Preclinical validation of anti-TMEFF2-auristatin E- conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther, 3: 921-32.

Horvath, L. G., S. M. Henshall, J. G. Kench, D. N. Saunders, C. S. Lee, D. Golovsky, P. C. Brenner, G. F. O’Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2004. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin Cancer Res, 10: 615-25.

Horvath, L. G., S. M. Henshall, J. G. Kench, J. J. Turner, D. Golovsky, P. C. Brenner, G. F. O’Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2004. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate, 59: 234-42. https://doi.org/10.1002/pros.10361″

Bauskin, A. R., D. A. Brown, S. Junankar, K. K. Rasiah, S. Eggleton, M. Hunter, T. Liu, D. Smith, T. Kuffner, G. J. Pankhurst, H. Johnen, P. J. Russell, W. Barret, P. D. Stricker, J. J. Grygiel, J. G. Kench, S. M. Henshall, R. L. Sutherland, and S. N. Breit. 2005. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res, 65: 23 https://doi.org/10.1158/0008-5472.can-04-3827

Horvath, L. G., S. M. Henshall, C. S. Lee, J. G. Kench, D. Golovsky, P. C. Brenner, G. F. O’Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2005. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer, 113: 415-22. https://doi.org/10.1002/ijc.20599″

Rasiah, K. K., J. G. Kench, M. Gardiner-Garden, A. V. Biankin, D. Golovsky, P. C. Brenner, R. Kooner, F. O’Neill G, J. J. Turner, W. Delprado, C. S. Lee, D. A. Brown, S. N. Breit, J. J. Grygiel, L. G. Horvath, P. D. Stricker, R. L. Sutherland, and S. M. Henshall. 2006. ”Aberrant neuropeptide Y and macrophage inhibitory cytokine expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev, 15: 711-6. https://doi.org/10.1158/1055-9965.epi-05-0752″

Ho, L. L., J. G. Kench, D. J. Handelsman, G. L. Scheffer, P. D. Stricker, J. G. Grygiel, R. L. Sutherland, S. M. Henshall, J. D. Allen, and L. G. Horvath. 2008. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate, 68: 1421-9. https://doi.org/10.1002/pros.20809″

Sakko, A. J., M. S. Butler, S. Byers, B. J. Reinboth, J. Stahl, J. G. Kench, L. G. Horvath, R. L. Sutherland, P. D. Stricker, S. M. Henshall, V. R. Marshall, W. D. Tilley, D. J. Horsfall, and C. Ricciardelli. 2008. Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol Biomarkers Prev, 17: 2488-97. https://doi.org/10.1158/1055-9965.epi-08-0204″

Rasiah, K. K., M. Gardiner-Garden, E. J. Padilla, G. Moller, J. G. Kench, M. C. Alles, S. A. Eggleton, P. D. Stricker, J. Adamski, R. L. Sutherland, S. M. Henshall, and V. M. Hayes. 2009. HSD17B overexpression, an independent biomarker of poor patient outcome in prostate cancer.Mol Cell Endocrinol, 301: 89-96. https://doi.org/10.1016/j.mce.2008.11.021″

Bianco-Miotto, T., K. Chiam, G. Buchanan, S. Jindal, T. K. Day, M. Thomas, M. A. Pickering, M. A. O’Loughlin, N. K. Ryan, W. A. Raymond, L. G. Horvath, J. G. Kench, P. D. Stricker, V. R. Marshall, R. L. Sutherland, S. M. Henshall, W. L. Gerald, H. I. Scher, G. P. Risbridger, J. A. Clements, L. M. Butler, W. D. Tilley, D. J. Horsfall, and C. Ricciardelli. 2010. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev, 19:2611-22. https://doi.org/10.1158/1055-9965.epi-10-0555″

Yip, P. Y., J. G. Kench, K. K. Rasiah, R. P. Benito, C. S. Lee, P. D. Stricker, S. M. Henshall, R. L. Sutherland, and L. G. Horvath. 2011. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. Prostate, 71: 1638-45. https://doi.org/10.1002/pros.21381″

Selth, L. A., S. L. Townley, A. G. Bert, P. D. Stricker, P. D. Sutherland, L. G. Horvath, G. J. Goodall, L. M. Butler, and W. D. Tilley. 2013. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer, 109: 641-50. https://doi.org/10.1038/bjc.2013.369″

Birch, S. E., J. G. Kench, E. Takano, P. Chan, A. L. Chan, K. Chiam, A. S. Veillard, P. Stricker, S. Haupt, Y. Haupt, L. Horvath, and S. B. Fox. 2014. Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death.. Ann Oncol, 25: 2392-7. https://doi.org/10.1093/annonc/mdu454″

Kalsbeek, A. M., E. F. Chan, J. Grogan, D. C. Petersen, W. Jaratlerdsiri, R. Gupta, R. J. Lyons, A. M. Haynes, L. G. Horvath, J. G. Kench, P. D. Stricker, and V. M. Hayes. 2016. Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer. Aging (Albany NY), 8: 2702-12. https://doi.org/10.18632/aging.101044″

Zhang, A. Y., J. S. Grogan, K. L. Mahon, K. Rasiah, P. Sved, D. R. Eisinger, J. Boulas, A. Vasilaris, S. M. Henshall, P. D. Stricker, J. G. Kench, and L. G. Horvath. 2017. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.. Ann Oncol, 28: 1903-09. https://doi.org/10.1093/annonc/mdx247″

Kalsbeek, A. M. F., E. K. F. Chan, J. Grogan, D. C. Petersen, W. Jaratlerdsiri, R. Gupta, R. J. Lyons, A. M. Haynes, L. G. Horvath, J. G. Kench, P. D. Stricker, and V. M. Hayes. 2018. Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer. Prostate, 78: 25-31. https://doi.org/10.1002/pros.23440″

Lin, H. M., B. Y. Lee, L. Castillo, C. Spielman, J. Grogan, N. K. Yeung, J. G. Kench, P. D. Stricker, A. M. Haynes, M. M. Centenera, L. M. Butler, S. M. Shreeve, L. G. Horvath, and R. J. Daly. 2018. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate, 78: 308-17. https://doi.org/10.1002/pros.23476″

Mahon, K. L., P.Stricker, J. Kench, J. Grogan, W. Delprado, J. Turner, L. Horvath, and D. I. Quinn. 2018. P53 as a predictor of clinical outcome in localized prostate cancer. Journal of Clinical Oncology, 36: 57-57. https://doi.org/10.1200/JCO.2018.36.6_suppl.57″

Nair, S.S., PL. Luu, W. Qu, M. Maddugoda, L. Huschtscha, R. Reddel, G. Chenevix-Trench, M. Toso, J. G. Kench, L.G. Horvath, V. M. Hayes, P. Stricker, T.P. Hughes, D.L. White, J.E. J. Rasko, J.J-L Wong, and S.J. Clark. 2018. Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. Epigenetics & Chromatin, 11: 24. https://doi.org/10.1186/s13072-018-0194-0″

Pidsley, R., M. G. Lawrence, E. Zotenko, B. Niranjan, A. Statham, J. Song, R. M. Chabanon, W. Qu, H. Wang, M. Richards, S. S. Nair, N. J. Armstrong, H. T. Nim, M. Papargiris, P. Balanathan, H. French, T. Peters, S. Norden, A. Ryan, J. Pedersen, J. Kench, R. J. Daly, L. G. Horvath, P. Stricker, M. Frydenberg, R. A. Taylor, C. Stirzaker, G. P. Risbridger, and S. J. Clark. 2018. Enduring epigenetic landmarks define the cancer microenvironment.. Genome Research, , 28: 625-38. https://doi.org/10.1101/gr.229070.117″

Jaratlerdsiri, W., E. K. F. Chan, T. Gong, D. C. Petersen, A. M. F. Kalsbeek, P. A. Venter, P. D. Stricker, M. R. Bornman, and V. M. Hayes. 2018. Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naive, High-Risk Prostate Cancer. Cancer Res. https://doi.org/10.1158/0008-5472.can-18-0254″

Bruce, HM., P.D. Stricker, R. Gupta, R.R. Savdie, AM. Haynes, KL. Mahon, HM Lin, JG. Kench, and LG. Horvath. 2016. Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer. The Prostate, 76: 1491-500. https://doi.org/10.1002/pros.23233″

Bancroft, E. K., S. Saya, E. C. Page, K. Myhill, S. Thomas, J. Pope, A. Chamberlain, R. Hart, W. Glover, J. Cook, D. J. Rosario, B. T. Helfand, C. Hutten Selkirk, R. Davidson, M. Longmuir, D. M. Eccles, N. Gadea, C. Brewer, J. Barwell, M. Salinas, L. Greenhalgh, M. Tischkowitz, A. Henderson, D. G. Evans, S. S. Buys, R. A. Eeles, IMPACT Collaborators* and N. K. Aaronson (2019). “Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. BJU Int 123(2): 284-292. https://doi.org/10.1111/bju.14412″ *Stricker, P. D. is an author under the IMPACT Collaborators

Feng, Y., W. Jaratlerdsiri, S. M. Patrick, R. J. Lyons, A. M. Haynes, C. C. Collins, P. D. Stricker, M. S. R. Bornman and V. M. Hayes (2019). etagenomic analysis reveals a rich bacterial content in high- risk prostate tumors from African men. Prostate 79(15): 1731-1738. https://doi.org/10.1002/pros.23897″

Quinn, D. I., P. D. Stricker, J. G. Kench, J. Grogan, A. M. Haynes, S. M. Henshall, J. J. Grygiel, W. Delprado, J. J. Turner, L. G. Horvath and K. L. Mahon (2019). “p53 nuclear accumulation as an early indicator of lethal prostate cancer. Br J Cancer 121(7): 578-583. https://doi.org/10.1038/s41416-019-0549-8″

Crumbaker, M., E. K. F. Chan, T. Gong, N. Corcoran, W. Jaratlerdsiri, R. J. Lyons, A. M. Haynes, A. A. Kulidjian, A. M. F. Kalsbeek, D. C. Petersen, P. D. Stricker, C. A. M. Jamieson, P. I. Croucher, C. M. Hovens, A. M. Joshua and V. M. Hayes (2020). “The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. Cancers (Basel) 12(5). https://doi.org/10.3390/cancers12051178.”

Sunny Z. Wu, Daniel L. Roden, Ghamdan Al-Eryani, Nenad Bartonicek, Kate Harvey, Aurélie S. Cazet, Chia-Ling Chan, Simon Junankar, Mun N. Hui, Ewan A. Millar, Julia Beretov, Lisa Horvath, Anthony M. Joshua, Phillip Stricker, James S. Wilmott, Camelia Quek, Georgina V. Long, Richard A. Scolyer, Bertrand Z. Yeung, Davendra Segara, Cindy Mak, Sanjay Warrier, Joseph E. Powell, Sandra O’Toole, Elgene Lim and Alexander Swarbrick. Cryopreservation of human cancers conserves tumour heterogeneity for single- cell multi-omics analysis: Wu et al. Genome Medicine (2021) 13:81 https://doi.org/10.1186/s13073-021-00885-z

Hui-Ming Lin, Nicole Yeung, Blossom Mak, Kevin Huynh, Thomas Meikle, Natalie Mellett, Edmond Kwan, Heidi Fettke, Ben Tran, Ian Davis, Kate Mahon, Alison Zhang, Martin R. Stockler, Karen Briscoe, Gavin Marx, Megan Crumbaker, Phillip Stricker, Pan Du, Jianjun Yu, Shidong Jia, Anthony M. Joshua, Arun Azad, Lisa M. Butler, Peter J. Meikle, Lisa G. Horvath. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedcine, 2021. Volume 72, 103625. https://doi.org/10.1016/j.ebiom.2021.103625″

Sadsad R., Brum I., Mutambirwa S., Stricker P., Bomman R. & Horvath, L. (2021). African-specific prostate cancer molecular taxonomy. Research Square 1 Dec 2021. https://doi.org/10.21203/rs.3.rs-1122619/v1″

Hui-Ming Lin, Blossom Mak, Nicole Yeung, Kevin Huynh, Thomas G. Meikle, Natalie A. Mellett, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis, Kate L. Mahon, Alison Zhang, Martin R. Stockler, Karen Briscoe, Gavin Marx, Megan Crumbaker, Phillip D. Stricker, Pan Du, Jianjun Yu, Shidong Jia, Tahlia Scheinberg, Michael Fitzpatrick, Paul Bonnitcha, David R. Sullivan, Anthony M. Joshua, Arun A. Azad, Lisa M. Butler, Peter J. Meikle, Lisa G. Horvath. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. eBioMedicine, Volume 72, 2021,103625, ISSN 2352-3964, https://doi.org/10.1016/j.ebiom.2021.103625.

Michèle Orain , Valérie Picard , Hélène Hovington , Alain Bergeron , Louis Lacombe , Yves Fradet , Bernard Têtu , Weerachi Jaratlerdsiri , Eva Chan , Vanessa Haynes , Robert Lesurf , Yu-Jia Shiah , Dr Lawrence E Heisler , Shadrielle Melijah Espiritu , Vincent Huang , Christopher Lalansingh , Richard Jovelin , Vinayak Bhandari , Dorota Sendorek , Stephenie Prokopec , Michael Fraser , Adrien Foucal , Veronica Sabelnykova , Dr Jüri Reimand , Professor Phillip Stricker , Andrew Ryan , Dr Theo van der Kwast , John D. McPherson , Takafumi Yamaguchi, Julie Livingstone , Natalie S Fox , Adriana Salcedo , Dr Kathleen E Houlahan , Lydia Liu , Professor Robert G Bristow , Natalie Kurganovs , Dr Chol-Hee Jung , Peter Georgeson , Ken Chow , Dr Michael Clarkson , Anne Nguyen , Ryan Stuchbery , Dr Marek Cmero , Patrick McCoy , Andrew Lonie , Justin Peters , Matthew Wakefield , Daniel Park , Michael Kerger , Anthony Costello , Dr Bernard Pope , Niall M Corcoran , Christopher M Hovens , Ms Helen Zhu , Professor Riana Bornman , Jocelyn Sietsma Penington , Stefano Mangiola, Lachlan Mcintosh , Professor Anthony T Papenfuss. Molecular and Evolutionary Origins of Prostate Cancer Grade. Nature NATCANCER-AN08058. 2022 11 Oct. https://mts-natcancer.nature.com/cgi-bin/main.plex?el=A6DB3DYT3A6BNZg7F4A9ftdqAS4qLnCYlFi706OfFBbkgZ

Gong T, Jaratlerdsiri W, Jiang J, Willet C, Chew T, Patrick SM, Lyons RJ, Haynes AM, Pasqualim G, Brum IS, Stricker PD, Mutambirwa SBA, Sadsad R, Papenfuss AT, Bornman RMS, Chan EKF, Hayes VM. Genome-wide interrogation of structural variation reveals novel African-specific prostate cancer oncogenic drivers. Genome Med. 2022 Aug 31;14(1):100. https://doi.org/10.1186/s13073-022-01096-w” PMID: 36045381; PMCID: PMC9434886

Craddock J, Jiang J, Patrick SM, Mutambirwa SBA, Stricker PD, Bornman MSR, Jaratlerdsiri W, Hayes VM. Alterations in the Epigenetic Machinery Associated with Prostate Cancer Health Disparities. Cancers (Basel). 2023 Jul 1;15(13):3462. https://doi.org/10.3390/cancers15133462″. PMID: 37444571; PMCID: PMC10341375.

Peters, T. J., Meyer, B., Ryan, L., Achinger-Kawecka, J., Song, J., Campbell, E. M., Qu, W., Nair, S., Loi-Luu, P., Stricker, P., Lim, E., Stirzaker, C., Clark, S. J., & Pidsley, R. (2024). Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling. BMC genomics, 25(1), 251. https://doi.org/10.1186/s12864-024-10027-5

Other

Stricker, P. D., A. B. F. Grant, B. M. Hosken, and J. S. Taylor. 1987. ‘Topical Mitomycin C Therapy for Carcinoma of the Bladder. The Journal of Urology, 138: 1164-66. https://doi.org/10.1016/S0022-5347(17)43537-3″

Stricker, P.D., and A. B. F. Grant. 1988. ‘Relative Value of Antibiotics and Catheter Care in the Prevention of Urinary Tract Infection after Transurethral Prostatic Resection. British Journal of Urology, 61:494-97. https://doi.org/10.1111/j.1464-410X.1988.tb05087.x”

Stricker, P. D., A. B. F. Grant, B. M. Hosken, and J. S. Taylor. 1990. ‘Topical Mitomycin C Therapy for Carcinoma in Situ of the Bladder: A Followup. The Journal of Urology, 143: 34-35. https://doi.org/10.1016/S0022-5347(17)39855-5″

Stricker, P. D. 1991. The Investigation of Male Sexual Dysfunction (Review). Medical Journal of Australia.

Pryor, K., J. Goddard, D. Goldstein, P. Stricker, P. Russell, D. Golovsky, and R. Penny. 1995. ‘Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer, 71: 801-7.

Pryor, K., P. Stricker, P. Russell, D. Golovsky, and R. Penny. 1995. ‘Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother, 41: 309-16.

Stricker, P. 1995. Advances in the treatment of superficial bladder cancer: Optimising BCG Immunotherapy Case Discussions. European Urology: Supp 32-33.

Millard, R. J., P. D. Stricker, and W. Lynch. 1996. ‘Risks of self-injection therapy for impotence. The Medical Journal of Australia, 165: 117-18.

Stricker, P. 1996. ‘Prostate Cancer: Don’t be too casual. The Medical Journal of Australia, 164: 319-20.

Stricker, P., K. Pryor, T. Nicholson, D. Goldstein, D. Golovsky, R. Ferguson, P. Nash, S. Ehsman, J. Rumma, G. Mammen, and R. Penny. 1996. ‘Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology, 48: 957-61; discussion 61-2.

Frydenberg, M., P. D. Stricker, and K. W. Kaye. 1997. ‘Prostate cancer diagnosis and management. The Lancet, 349: 1681-87. https://doi.org/10.1016/S0140-6736(96)07393-X”

Frydenberg, M, G. Duchesne, and P. D. Stricker. 1998. ‘Management of localised prostate cancer: state of the art. Med J Aust,169: 11- 2.

Russell, P. J., S. Bennett, and P. Stricker. 1998. ‘Growth factor involvement in progression of prostate cancer. Clin Chem, 44: 705-23.

Kooner, R, and P. Stricker. 2000. Lower urinary tract symptoms in the male. Benign prostatic hyperplasia. MedicineToday: 20-33.

Stricker, P. 2001. Prostate Cancer Part 1. Issues in Screening and Diagnosis. MedicineToday: 20-31.

Stricker, P. 2001. Prostate Cancer Part 2. – Options in Treatment. MedicineToday, 2: 30-38.

Cagiannos, I., P. Karakiewicz, J. A. Eastham, M. Ohori, F. Rabbani, C. Gerigk, V. Reuter, M. Graefen, P. G. Hammerer, A. Erbersdobler, H. Huland, P. Kupelian, E. Klein, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, C. G. Morash, P. T. Scardino, and M. W. Kattan. 2003. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol, 170:1798-803. https://doi.org/10.1097/01.ju.0000091805.98960.13″

Rasiah, K. K., P. D. Stricker, A. M. Haynes, W. Delprado, J. J. Turner, D. Golovsky, P. C. Brenner, R. Kooner, G. F. O’Neill, J. J. Grygiel, R. L. Sutherland, and S. M. Henshall. 2003. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer, 98: 2560-5. https://doi.org/10.1002/cncr.11850″

Adshead, J, and P. Stricker. 2004. Localised Prostate Cancer – Questions Patients Ask. MedicineToday, 5: 18-32.

Haxhimolla, H, S.P. David, K. K. Rasiah, A. M. Haynes, K Luo, D. Golovsky, and P. Stricker. 2004. Solitary positive apical margin a treatment dilema. ANZ Journal of Surgery, 74: A1-A8.

Hoch, M, K. K. Rasiah, H Haxhimolla, A. M. Haynes, and P. Stricker. 2004. Determining predictors of insignificant cancer in Gleason sum 6 prostate cancer. ANZ Journal of Surgery, 74.

Rasiah, K. K., S. M. Henshall, J. G. Kench, L. G. Horvath, D. Golovsky, P. C. Brenner, R Kooner, G. O’Neill, J. J. Turner, W. Delprado, C. S. Lee, and P.D. Stricker. 2004. Identification of novel markers of prognosis in high grade intraepithelial neoplasia and early prostate cancer. ANZ Journal of Surgery, 74: A1-A8.

Finney, G., A. M. Haynes, P. Cross, P. Brenner, A. Boyn, and P. Stricker. 2005. Cross-sectional analysis of sexual function after prostate brachytherapy. Urology, 66: 377-81. https://doi.org/10.1016/j.urology.2005.03.045″

Karakiewicz, P. I., J. A. Eastham, M. Graefen, I. Cagiannos, P. D. Stricker, E. Klein, T. Cangiano, F. H. Schroder, P. T. Scardino, and M. W. Kattan. 2005. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology, 66: 1245-50. https://doi.org/10.1016/j.urology.2005.06.108″

Macek, P, D Patel, and P. Stricker. 2005. Assessing and managing benign prostatic hyperplasia. MedicineToday, 6: 12-22.

Chabert, C., Z. Maianski, and P. Stricker. 2007. Saw palmetto and lower urinary tract symptoms in men. MedicineToday, 8: 71-72.

Chabert, C., and P. Stricker. 2009. Treatment for Localised Prostate Cancer. MedicineToday, 10: 63-66.

Smith, David P, Madeleine T King, Sam Egger, Martin P Berry, Phillip D Stricker, Paul Cozzi, Jeanette Ward, Dianne L O’Connell, and Bruce K Armstrong. 2009. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ, 339. https://doi.org/10.1136/bmj.b4817″

Stricker, P. 2009. A Practical Guide on PSA Testing. MedicineToday, 10.

Yuen, C., and P. Stricker. 2011. Advances in the management of benign prostatic hyperplasia. MedicineToday, 12.

Stricker P.D., Frydenberg M., Kneebone A., and Chopra S..2012. Informed prostate cancer risk‐adjusted testing: a new paradigm. BJU International, 110: 30-34. https://doi.org/10.1111/j.1464-410X.2012.11621.x”

King, M. T., R. Viney, D. P. Smith, I. Hossain, D. Street, E. Savage, S. Fowler, M. P. Berry, M. Stockler, P. Cozzi, P. Stricker, J. Ward, and B. K. Armstrong. 2012. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. British Journal of Cancer, 106: 638-45. https://doi.org/10.1038/bjc.2011.552″

Smith, D., D O’Connell, A Bang, M. T. King, M. P. Berry, P. Stricker, P. Cozzi, and B. K. Armstrong. 2012. Survival in men diagnosed with prostate cancer: 8 to 10 year outcomes from the NSW Prostate Cancer Care and Outcomes Study. Abstract for Sydney Cancer Conference.

Yuen, C., T Hoassack, A. M. Haynes, R. DeBenito, J Mathews, G. Fogarty, R. S. Jagavkar, P. Brenner, and P. Stricker. 2012. Impact of percentage of positive biopsy cores on biochemical outcome in patients treated with low-dose rate (Iodine-125) brachytherapy for prostate cancer. The Open Prostate Cancer Journal, 5: 15-19.

Symons, J. L., A. Huo, C. L. Yuen, A. M. Haynes, J. Matthews, R. L. Sutherland, P. Brenner, and P. D. Stricker. 2013. Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int, 112: 585-93. https://doi.org/10.1111/j.1464-410X.2012.11657.x”

Thanigasalam, R., H. Baumert, P. Stricker, P. Brenner, S. Egger, S. Chopra, J. Symons, R. Savdie, A. Haynes, M. Bohm, A. Elhajj, D. Smith, R. Sutherland, and K. Rasiah. 2013. Évaluation de la qualité de vie suite aux traitements actuels du cancer de prostate localisé. Progrès en Urologie, 23: 1100. https://doi.org/10.1016/j.purol.2013.08.187″

Tran, M, and P. Stricker. 2014. An Update on the medical management of benign prostatic hypertrophy. MedicineToday, 15: 72-76.

Gupta, R., R. O’Connell, A. M. Haynes, P. D. Stricker, W. Barrett, J. J. Turner, W. Delprado, L. G. Horvath, and J. G. Kench. 2015. Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?. BJU Int, 116: 343-50. https://doi.org/10.1111/bju.12911″

Rhee, H., J. H. Gunter, P. Heathcote, K. Ho, P. Stricker, N. M. Corcoran, and C. C. Nelson. 2015. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int, 115 Suppl 5: 3-13. https://doi.org/10.1111/bju.12964″

Ting, F., P. J. van Leeuwen, W. Delprado, A. M. Haynes, P. Brenner, and P. D. Stricker. 2015. Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment. Prostate, 75: 1768-73. https://doi.org/10.1002/pros.23062″

Tran, M, and P. Stricker. 2015. An update on the medical management of prostate cancer. MedicineToday, 16: 42-48.

Penzias, G., A. Janowczyk, A. Singanamalli, M.Rusu, N. Shih, M. Feldman, P. D. Stricker, W. Delprado, S. Tiwari, M. Böhm, A.M. Haynes, L. Ponsky, S.Viswanath, and A. Madabhushi. 2016. AutoStitcher: An Automated Program for Efficient and Robust Reconstruction of Digitized Whole Histological Sections from Tissue Fragments. Scientific Reports, 6: 29906. https://doi.org/10.1038/srep29906″

van Leeuwen, P. J., A. Siriwardana, M. Roobol, F. Ting, D. Nieboer, J. Thompson, W.Delprado, A.M. Haynes, P. Brenner, and P. Stricker. 2016. Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies. Prostate Cancer, 2016: 7. https://doi.org/10.1155/2016/7105678″

Siriwardana, A., J. Thompson, and P. Stricker. 2017. Personalising prostate cancer care. Part 1: Advances in diagnosis. MedicineToday, 18: 29-32.

Siriwardana, A., J. Thompson, and P. Stricker. 2017. Personalising prostate cancer care. Part 2: Current treatment options. MedicineToday, 18: 28-33.

Symons, J., and P. Stricker. 2017. “Transperineal Prostate Biopsy. In Hinman’s Atlas of Urologic Surgery. Elsevier.

Van den Bos, W., and P. Stricker. 2017. Editorial Comment. The Journal of Urology, 197: 653-54. https://doi.org/10.1016/j.juro.2016.09.137″

Gielchinsky, I., J. Chang, T. Cusick, W. Delprado, Q. Nguyen, C. Yuen, R. Savdie, M. Bohm, A. M. Haynes, M. J. Scheltema, and P. D. Stricker. 2018. Prostate cancer in 432 men aged < 50 years in the prostate-specific antigen era: a new outlook. BJU Int, https://doi.org/10.1111/bju.14586″

Lam, T. B. L., S. MacLennan, P. M. Willemse, M. D. Mason, K. Plass, R. Shepherd, R. Baanders, C. H. Bangma, A. Bjartell, A. Bossi, E. Briers, A. Briganti, K. T. Buddingh, J. W. F. Catto, M. Colecchia, B. W. Cox, M. G. Cumberbatch, J. Davies, N. F. Davis, M. De Santis, P. Dell’Oglio, A. Deschamps, J. F. Donaldson, S. Egawa, C. D. Fankhauser, S. Fanti, N. Fossati, G. Gandaglia, S. Gillessen, N. Grivas, T. Gross, J. P. Grummet, A. M. Henry, A. Ingels, J. Irani, M. Lardas, M. Liew, D. W. Lin, L. Moris, M. I. Omar, K. H. Pang, C. C. Paterson, R. Renard-Penna, M. J. Ribal, M. J. Roobol, M. Roupret, O. Rouviere, G. Sancho Pardo, J. Richenberg, I. G. Schoots, J. P. M. Sedelaar, P. Stricker, D. Tilki, S. Vahr Lauridsen, R. C. N. van den Bergh, T. Van den Broeck, T. H. van der Kwast, H. G. van der Poel, G. van Leenders, M. Varma, P. D. Violette, C. J. D. Wallis, T. Wiegel, K. Wilkinson, F. Zattoni, J. M. O. N’Dow, H. Van Poppel, P. Cornford and N. Mottet (2019). AU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol. https://doi.org/10.1016/j.eururo.2019.09.020″

Books, Chapters and DVDs

1995Tumour Markers and Flow Cytometry. Chapter in book “The Bladder”. Fitzpatrick and Krane. Chapter by P.Stricker and P.Russell. Pg 385–394. 2000 The Australian Medical Association. “Home Medical Guide to Prostate Disorders”. Consulting Editor. 2003 “Treatment of Localised Prostate Cancer”. Member of the Prostate Cancer Working for Cancer Network Australia. 2004 “PSA for the General Practitioner” Book. P.Stricker and K. Phelps. 2008 “Prostate Cancer for the General Practitioner.” Book P. Stricker and K.Phelps. 2008 “So I Have Prostate Cancer, What Now?” PCFA DVD 2009 “How Do You Choose” DVD. P Stricker 2010 “Intergrative Medicine for the General Practitioner” Book. Hassad and Phelps. Chapter on prostate cancer. 2012 Series of DVDs:”Pelvic Floor Exercises, Moving Forward”,”Prevention & Localised Prostate Cancer”,

“Advanced Prostate Cancer & Hormone Treatments”,

“Cured of Prostate Cancer – What About Quality of Life”,

“Return to Potency after Prostate Cancer”,

“Prostate Cancer Treatments – Managing Side Effects”,

“Prostate Cancer – Integrative Medicine Taking Control”,

“Prostate Cancer – Urinary Control”,

“Advanced Prostate Cancer” – Prof. Charles Myers,

“Prostate Cancer – managing the Mind”,

“Robotic Surgery – The Journey”.

2013 “Improving outcomes in robotic radical prostatectomy.” Chapter 7. Editor Vip Patel. 2014–15 “Clinical Practice Guidelines for PSA Testing & Early Management of Test–Detected Prostate Cancer” Prostate Cancer Foundation of Australia & Cancer Council Australia. NHMRC approved. Part of the expert advisory panel 2018 Early detection and screening for prostate cancer. Chapter in the book “Evidence–Based Urology”, 2nd Edition. Dahm and Dmochowski. Pgs. 257–265. Chapter by P. van Leeuwen, M.J. Roobol and P.D. Stricker. 2019 Urology Fellowship Handbook: A Concise Guide to Clinical Urology. Chapter in the book as co–author with other urologists, Chapter 18–20, Pgs 606. Authors Matthew Winter and Venu Chalasani 2019 Hinman’s Atlas of urologic surgery – (Revised Reprint), 4th Edition– Chapter on Transperineal Biopsy

Symposia Convened (National and International)

1. Impotence Symposium of Australasia – Operative Workshop St Vincent’s Hospital – 1991. Editor of Monograph. Presentations on “Intracorporeal Pharmacotherapy – Results and Complications” – P. Stricker (T.Dean) & “Polypharmacotherapy” – P.Stricker (L.Jacobs) Convener
2. Update of Urology for GP’s University of NSW 1993. Presentations on Renal calculi, Prostate cancer & Impotence Convener
3. Society Internationale d’Urologie 23rd Congress Meeting Sydney. 1994. Editor of daily proceedings & Presenter
4. Prostate Cancer Symposium – Operative Workshop St Vincent’s Clinic 1995. Editor of Monograph. Presentation on “Radical Perineal Prostatectomy – St Vincent’s Experience”. Convener
5. Impotence Management Symposia. P Stricker – Chairman of Australian Impotence Advisory Board 1995
6. Australian Society of Impotence Medicine Inaugural Meeting 1997. 4 Presentations & Surgical Workshop Co Convener
7. Inaugural National GUOG Meeting (Leura). Presentations & Workshop on Prostate Cancer Surgery Co Convener
8. Brachytherapy for Prostate Cancer Symposium with J.Blasko St Vincent’s Hospital. 1997 Convener and Demonstrated
9. Prostate Cancer Symposium – Presentation on Radical Prostatectomy Garvan Institute. 1999 Convener
10. Benign Prostatic Hypertrophy – Laser Prostatectomy St Vincent’s Hospital. 1999 Co Convener
11. Prostate Cancer Update with Peter Scardino – Operative Workshop St Vincent’s Hospital. 2001 Convener
12. Laparoscopic Radical Prostatectomy – Operative Workshop St Vincent’s Hospital. 2003 Convener R.Kooner & P.Stricker
13. Brachytherapy Workshop with Michael Zelefsky – Operative Workshop St Vincent’s Hospital 2005. Convener
14. Robot Assisted Radical Prostatectomy with Vip Patel – Operative Workshop St Vincent’s Hospital 2007. Convener.
15. MRI of the Prostate – A Multidisciplinary Symposium – May 2012. Co– convener.
16. Focal Therapy, Imaging & Biopsy Techniques with Mark Emberton Operative Workshop St Vincent’s Hospital, 2013. Convener.

Presentations (National and International)

From 2013 onwards

1. Beattie K and Stricker P. Prevalence of high–risk features in radical prostatectomy specimens in patients who met criteria for nerve– sparing radical prostatectomy. Oral presentation at the Urological Society of Australia and New Zealand (USANZ) NSW section meeting. 9–12 Nov 2013, Hamilton Island, Australia
2. Thompson J and Stricker P. Comparison between the accuracy of 12, 16 and 20 core TRUS biopsy in detecting significant prostate cancer and correlation with grade and location on radical prostatectomy. Oral presentation at the Urological Society of Australia and New Zealand (USANZ) NSW section meeting. 9–12 Nov 2013, Hamilton Island, Australia
3. Thompson J and Stricker P. Superior Quality of Life and Improved Surgical Margins Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve: A Prospective Single– surgeon Study of 1552 Consecutive Cases. Oral presentation at the Urological Society of Australia and New Zealand (USANZ) NSW section meeting. 9–12 Nov 2013, Hamilton Island, Australia
4. Tran M, Jackson B, Boehm M, Haynes A–M, Stricker P, Irreversible Electroporation for Focal Prostate Cancer: Safety, Short–term Functional and Oncological Outcomes. Poster Presentation. 68th Urological Society of Australia and New Zealand Annual Scientific Meeting 11th – 19th April 2015, Adelaide, South Australia
5. Tiwari S, Haynes A–M, Nguyen Q, Hammond G, Kench JG, Horvath LG, Stricker PD. A Prostate Cancer Biorepository meeting International Collaborative Demands. Poster Presentation. International Society for Biological and Environmental Repositories (ISBER) 2015 Annual Meeting and Exhibits 5–9 May 2015, Phoenix Arizona, USA
6. Tiwari S, Haynes A–M, Nguyen Q, Hammond G, Kench JG, Horvath LG, Stricker PD. The Garvan Query Application (GQA): A Comprehensive Search Engine for a Prostate Cancer Biorepository. Poster Presentation. International Society for Biological and Environmental Repositories (ISBER) 2015 Annual Meeting and Exhibits 5– 9 May 2015, Phoenix Arizona, USA
7. Thompson J, Shnier R, Moses D, Brenner P, Delprado W, Tran M, Ponsky L, Boehm M, Hayen A, Stricker P. Oral Presentation. Prospective study of pre–biopsy multiparametric magnetic resonance imaging (mpMRI) compared to transperineal template mapping biopsy (TTMB) for detection of clinically significant prostate cancer: is it accurate enough to guide selection of men for biopsy? Oral Presentation. American Urological Association Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA
8. Tran M, Thompson J, Boehm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes A–M, Savdie R, Stricker P. Combination of multi–parametric magnetic resonance imaging (mp–MRI) and transperineal template–guided mapping biopsy (TTMB) of the prostate to identify candidates for hemi–ablative focal therapy. Poster Presentation. American Urological Association Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA
9. Algohary A, Viswanath S, Prasanna P, Pahwa S, Gulani V, Moses D, Shnier R, Böhm M, Haynes A–M, Brenner P, Delprado W, Thompson J, Pulbrock M, Stricker P, Ponsky L, Madabhushi A. Quantitative assessment of T2–weighted MRI to better identify patients with prostate cancer in a screening population. Poster Presentation. American Urological Association Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA
10. Stricker PD. The role of focal therapy in localized prostate cancer, preliminary Australian results. Invited speaker. American Urological Association Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA
11. Stricker PD. Focal Therapy for Prostate Cancer Debate. Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA
12. Stricker PD. MRI nanogram for prostate cancer. Invited speaker. 16th Asia–Pacific Prostate Cancer Conference. Cairns Australia
13. Haynes A–M, Tiwari S, Nguyen Q, Abuodha M, Stricker P and Horvath L. The Pros and Cons of moving towards a modern method for the storage of blood samples in a research biorepository. Poster Presentation. International Society for Biological and Environmental Repositories (ISBER). 5–8 April 2016 Berlin, Germany
14. Siriwardana A, van Leeuwen PJ, Roobol M, Ting F, Nieboer D, Thompson J, Delprado W, Haynes A, Brenner P, and Stricker P. Predicting low–risk prostate cancer from transperineal saturation biopsies. USANZ 2016 Annual Scientific Meeting 16–19th April 2016, Gold Coast, Australia.
15. Siriwardana A, van Leeuwen PJ, Roobol M, Ting F, Nieboer D, Thompson J, Delprado W, Haynes A, Brenner P, and Stricker P. Predicting low–risk prostate cancer from transperineal saturation biopsies. American Urological Association Annual Meeting 2016 – 6–10th May, 2016. San Diego, USA.
16. Stricker PD. Nanoknife focal therapy. Invited speaker. 3rd Friends of Israel Urological Symposium 5–7th July 2016. Tel–Aviv, Israel.
17. Stricker PD. Surgery is better than radiotherapy debate. Invited speaker. 3rd Friends of Israel Urological Symposium 5–7th July 2016. Tel–Aviv, Israel.
18. Nguyen Q, Haynes AM, Horvath L and Stricker PD. Prostate Cancer Research: From Lab Bench to Beside: A prospective from the Trenches. Poster presentation. 9th Health Services and Policy Research Conference 7 – 9th Dec 2015. Melbourne, Australia
19. Nguyen Q, Stricker PD, Thompson B and Emmett L. Evaluating changes in clinical management following the introduction of Ga68–PSMA PET scans for the detection of prostate cancer. Poster presentation. Health Services Research United Kingdom (HSRUK) Symposium. 13–14 July 2016. Nottingham, United Kingdom
20. Van den Bos W, Stricker PD et al. Focal Therapy Using IRE in prostate cancer. Synergy Miami, November 2016. Miami Beach, Florida USA.
21. Siriwardana A, van den Bos W, Kalsbeek A, Thompson J, Ting F, Boehm M, Haynes A, Shnier R, Delprado W and Stricker PD. Focal Irreversible Electroporation (IRE) as a primary and salvage treatment for localised prostate cancer. USANZ 2017 Annual Scientific Meeting 24–27th February 2017, Canberra, Australia
22. Siriwardana A, Thompson J, Hayen A, Ting F, Delprado W, Brenner P, Ende D, Kooner R, O’Neill G, Yuen C, Tiwari S, Haynes A and Stricker P. Lymph node yield at radical prostatectomy is a predictor of biochemical recurrence–free survival (BFS) in high–risk prostate cancer patients. USANZ 2017 Annual Scientific Meeting 24–27th February 2017, Canberra, Australia
23. Siriwardana A, Thompson J, Doig S, Kalsbeek A, Emmett L, Delprado W, Wong D, Samaratunga H, Haynes A, Couglin G and Stricker PD. Robot–assisted Salvage Node Dissection For Oligometastatic Nodal Disease Detected By 68Gallium–PSMA PET/CT: A Multicentre Retrospective Series. USANZ 2017 Annual Scientific Meeting 24–27th February 2017, Canberra, Australia 2017 Keith Kirkland Prize Awarded
24. Stricker PD. My learning curve and improving patients erectile function recovery. Invited speaker. Sydney Robotic Summit: Research and Innovation. 24th June 2017 Sydney Australia.
25. Thompson JE, Egger S, Bohm M, Siriwardana A, Haynes AM, Matthews J, Scheltema M, Stricker PD. Superior biochemical recurrence and quality of life outcomes are achievable with robotic radical prostatectomy versus open radical prostatectomy – update of a prospective single–surgeon study of 2206 consecutive cases. 5th Global Congress on Prostate Cancer. 28 – 30 June 2017, Lisbon Portugal
26. Scheltema, MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF. Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W, Stricker PD. Focal Irreversible Electroporation as primary and salvage treatment for prostate cancer. 5th Global Congress on Prostate Cancer. 28 – 30 June 2017, Lisbon Portugal
27. Scheltema MJ, Chang JI, van den Bos, Bohm M, Delprado W, Gielchinsky I, de Reijke TM, de la Rosette J, Sirawardana AR, Shnier R, Stricker PD. Diagnostic Accuracy of Mulitparametric Resonance Imaging Following Prostate Cancer Focal Therapy with Irreversible Electroporation. 93rd Annual Meeting Western Section of the American Urological Association, 6 –10 August 2017, Vancouver British Columbia Canada
28. Scheltema MJ, Chang JI, van den Bos, Gielchinsky I, de Reijke TM, Sirawardana AR, Bohm M, de la Rosette J, Stricker PD. Genito– Urinary Function and Quality of Life after Focal Irreversible Electroporation of Different Prostate Segments. 93rd Annual Meeting Western Section of the American Urological Association, 6 –10 August 2017, Vancouver British Columbia Canada
29. Scheltema MJ, Chang JI, Bohm B, van den Bos W, Gielchinsky I, Kalsbeek AF, van Leeuwen PJ, de Reijke TM, Siriwardana AR, de la Rosette JJ. Stricker PD. Pair–matched Patient–reported Quality of Life following Focal Irreversible Electroporation versus Robot– assisted Radical Prostatectomy. 37th Congress of the Societe Internationale d’Urologie. 19–22 October 2017, Lisbon Portugal.
30. Chang J, Stricker PD Emmett L et al. False positive intraprostatic lesions on 68Ga Positron emission tomography in an intermediate prostate cancer cohort: Description of a benign cystic cellular pattern with intense PSMA activity. For Poster Presentation at USANZ 2018 in Melb 24–27th of February 2018.
31. Blazevski A, Yuen B, Scheltema MJ, Chang J, Masand N, Haynes AM, Nguyen Q, Stricker P. Is it time for prostate cancer’s lumpectomy? Focal irreversible electroporation (IRE) for localised clinically significant prostate cancer. 26th ASMR NSW ASM 2018
32. Blazevski A, Pidsley R, Qu W, Norbie D, Luu L, Chang J, Yuen B, Scheltema MJ, Masand N, Haynes AM, Nguyen Q, Stirzaker C, Song J, Stricker P, Clark S. When Focal Therapy Fails for Localised Prostate Cancer – Can Epigenetics Predict Which Patients Fail and Improve Patient Selection? ANZUP ASM 8 – 10 July 2018. Sydney, Australia.
33. Blazevski A, Yuen B, Scheltema MJ, Chang J, Masand N, Haynes AM, Nguyen Q, Stricker P. Focal irreversible electroporation as salvage treatment for localised radio–recurrent prostate cancer – Initial results and initiation of the FIRE trial. ANZUP ASM 8 – 10 July 2018. Sydney, Australia.
34. Stricker P, Blazevski A, Scheltema MJ, Thompson J, Haynes AM, Nyguen Q, Chang, J, Yuen B. Oncological outcomes of irreversible electroporation (Nanoknife) for localised clinically significant prostate cancer at single Australia centre. 6th Edition Global Congress on Prostate Cancer (PROSCA 2018). 28 – 30 June 2018. Frankfurt, Germany
35. Blazevski A, Yuen B, Scheltema MJ, Chang J, Masand N, Haynes AM, Nguyen Q, Stricker P. Is it time for prostate cancer’s lumpectomy? – Focal irreversible electroporation (IRE) for localised clinically significant prostate cancer. ASMR NSW Annual Scientific Meeting, June 2018. Sydney, Australia.
36. Blazevski A, Yuen B, Scheltema MJ, Chang K, Masand N, Haynes AM, Nguyen Q, Stricker P. 5 years of Irreversible Electroporation (Nanoknife) for Localised Prostate Cancer. Asia–Pacific Prostate Conference 2018. Brisbane, Australia.
37. Blazevski A, Yuen B, Mare A. Retrospective Multicentre Cohort Study of Urothelial Manipulating Investigations and their Effects on Recurrence and Oncological Outcome for Upper Tract Urothelial Carcinoma. 38th Congress of the Société Internationale d’Urologie. 4 – 7 October 2018. Seoul, Korea
38. Blazevski A, Yuen B, Scheltema MJ, Masand N, Haynes AM, Nguyen Q, Stricker P. Oncological Outcomes of Focal Irreversible Electroporation as Primary Treatment for Clinically Significant Localised Prostate Cancer. 38th Congress of the Société Internationale d’Urologie. 4 – 7 October 2018. Seoul, Korea
39. Blazevski A, Yuen B, Scheltema MJ, Masand N, Haynes AM, Nguyen Q, Stricker P. Application of the IDEAL Framework to the Introduction of a Novel Treatment for Localised Clinically Significant Prostate Cancer. 38th Congress of the Société Internationale d’Urologie. 4 – 7 October 2018. Seoul, Korea
40. Blazevski A, Stricker P. Where is the prostate cancer recurrence after radiation therapy? Implications for biopsy and focal salvage therapy. USANZ NSW Section Meeting. 1 – 3 November 2018. Cypress Lakes, Hunter Valley, NSW, Australia.
41. Blazevski A. Irreversible Electroporation (Nanoknife) for Localised Clinically Significant Prostate Cancer. Peter MacCallum Cancer Centre – Uro–Oncology Meeting July 2018. Melbourne, Victoria.
42. Blazevski A, Stricker P. Reduced Sensitivity of Multiparametric MRI for Clinically Significant Prostate Cancer in Men Under the Age of 50 – ACT RACS Annual Scientific Meeting 2018.
43. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Salvage Irreversible Electroporation for Locally Recurrent Prostate Cancer after Radiotherapy – Oncological and Functional Outcomes. USANZ Annual Scientific Meeting 2019. Brisbane, Queensland
44. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Update on 12–Month Biopsy Proven Oncological and Functional Outcomes of Primary Irreversible Electroporation for Localised Prostate Cancer. USANZ Annual Scientific Meeting 2019. Brisbane, Queensland
45. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Focal Irreversible Electroporation for Radiorecurrent Prostate Cancer – Update on Current Results and Establishment of the FIRE trial. TROG Annual Scientific Meeting 2019. Melbourne, Australia
46. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Shnier R, Stricker P. Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation. EAU 2019 – Annual Scientific Meeting – Barcelona.
47. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Update on 12–month biopsy proven oncological and functional outcomes of primary irreversible electroporation for localised prostate cancer. EAU 2019 – Annual Scientific Meeting – Barcelona.
48. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Salvage irreversible electroporation for locally recurrent prostate cancer after radiotherapy – Oncologic and functional outcomes. EAU 2019 – Annual Scientific Meeting – Barcelona.
49. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Shnier R, Stricker P. Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation. AUA 2019 – Annual Scientific Meeting – Chicago.
50. Blazevski A, Cusick T, Haynes AM, Stricker P. Evolution of Irreversible Electroporation into a prostate cancer treatment – From the laboratory to Urologists. AUA 2019 – Annual Scientific Meeting – Chicago.
51. Amin A, Blazevski A, Scheltema MJ, Stricker P, Thompson J. The MRI in active surveillance study (MRIAS): A prospective single arm cohort study replacing confirmatory biopsy with mpMRI in active surveillance for low risk prostate cancer – Asia–Pacific Prostate Cancer Conference 2019 – Melbourne, Australia.
52. Amin A, Blazevski A, Scheltema MJ, Thompson J, Stricker P. Salvage Radical Prostatectomy After Focal Irreversible Electroporation for Prostate Cancer: A Case Series Reporting Oncological Outcomes. Société International d’Urologie 2019 – Athens.
53. Gondoputro W, Thompson J. , Frydenberg M. , Murphy D.G. , Bolton D. , Stricker P. , Papa N. Does age affect continence outcomes following robot-assisted radical prostatectomy? Results from an Australian multi-institutional study: Clinical / Patient Reported Outcomes. Virtual Congress EAU21 Congress, 8-12 July 2021
54. Gondoputro W, Blazevski A, Amin A, Scheltema M, Agrawal S, Cusick T, Van Leeuwen P, Van Leeuwen F, Emmett L, Thompson J, Stricker P. Interim results from the DETECT Trial: A prospective clinical trial evaluating 99MTC-Labelled PSMA Radioguided surgery to aid the intraoperative detection of lymph node metastases during Robot-Assisted Radical Prostatectomy and extended pelvic lymph node dissection for prostate cancer. Virtual Congress AUA21 Congress, 12 September 2021
55. John N., Ho B., Pathmanandavel S., Counter W., Liu V., Lee J., Marripudi1 K., Chan L., Sharma S., Agrawal S., Hickey A., Stricker P., Eade T., Leon J., Joshua A., Nguyen A., & Louise Emmett. [64Cu]Cu-SAR-Bombesin ([64Cu]Cu-SAR-BBN) PET-CT for the detection of biochemically recurrent PSMA-PET negative prostate cancer: a case series. Poster presentation at ANZUP and RANZCR ASM to be presented 2022.
56. Geboers B., Gondoputro W., Thompson J., Reesink D., Van Riel L., hang D., Blazevski A., Doan P., Agrawal S., Matthews J., Haynes A., Liu Z., Delprado W., Shnier R., Reijke T., Lawrentschuk N., Stijns P., Yaxley J., Scheltema M. & Stricker P. Diagnostic accuracy of mpMRI to detect residual prostate cancer following Irreversible electroporation – a multicenter validation study: Presentation EAU Amsterdam Jul 2022
57. Geboers B., Gondoputro W., Ssceltema M., Doan P., Haynes A., Agrawal. S., Liu Z., Thompson J., Delprado W., O’Neill G., Yuen C., Lee J., Ho B., Stricker P. and Emmett L. Combining PSMA-PET/CT, mpMRI and transperineal mapping biopsies to select selection patients for focal hemi-ablation – a retrospective analysis: Presentation USANZ Gold Coast Jun 2022
58. Nieboer d et al, A0276: External validation of a model predicting increase in gleason grade for men on active surveillance in the GAP3 consortium database: Presentation EAU Amsterdam Jul 2022
59. Van Riel et al, A0966: Safety and feasibility of salvage prostatectomy following primary IRE treatment for recurrent localised prostate cancer: an international and multicentre analysis: Presentation EAU Amsterdam Jul 2022
60. Doan et al, Does synchronous versus independent reading of 68Ga-PSMA- 11 PET and multiparametric MRI improve diagnostic performance, concordance, and certainty for prostate cancer diagnosis: Presentation EAU Amsterdam Jul 2022
61. Doan et al, Final analysis of the Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Presentation EAU Amsterdam Jul 2022
62. Blazevski et al, Focal Therapy for prostate cancer 2022 – ready for prime time?: USANZ Goald Coast Jun 2022
63. Amer Amin, Outcomes for active surveillance are similar for men with favourable fisk ISUP 2 to those with ISUP 1 prostate cancer: A pair matched cohort study: USANZ Goald Coast Jun 2022
64. Prof Stricker, High Risk Prostate Cancer – What’s new: Keynote Speaker at the SRS Virtual Conference 2023
65. Prof Stricker, Salvage options for recurrence following radiotherapy. APCC 2023 Conference Program Aug 2023

International and National Invited Surgeon

1993 – Malaysian Urological Society

1995 – Korean Urological Society

2000 – Chinese Urological Society

2008 – Western Australian Urological Society – Robot Assisted Radical Prostatectomy

2009 – Queensland Australian Urological Society – Robot Assisted Radical Prostatectomy

Invited Speaker

1992

Australasian Urological Society Annual Meeting – Intravesical BCG. “Immunotherapy & Chemotherapy – 10 year experience”

1993

Australasian Ultrasound Society – Annual Meeting

1.Transrectal ultrasound for prostate.

2. Penile Duplex ultrasound.

New Zealand Urological Society –”Transurethral needle ablation of the prostate”. P.Stricker, G. Coombes.

Malaysian Urological Society – Incontinence & Collagen Implant

1994

International Urological Society – 23rd Congress

1. B.C.G. for Bladder cancer

2.Collagen for Stress Incontinence

3.TUNA for B.P.H.

8th Congress of World Ostomy Association – Adelaide.”Sexual consequence of Surgery”.

1996

Queensland Assert & Sexual Health Society Meeting. Specialised investigation of Impotence.

International Menopause Society

Symposium of male Sexual Dysfunction.

8th African Urological Society. Invited speaker “Peyronie’s and side effects of injection treatment”

1997

South Australian Urological Society Meeting. Presentations on:

1. Role of Surgery for prostate cancer

2. Peyronie’s Disease

3. Collagen Implant for Male Incontinence

South Africa Visiting Lecturer –”Peyronie’s Disease & Injection Therapy

1998

Annual Urological Society of Australia Meeting – Adelaide. “Peyronie’s Disease”

2000

Shanghai Urological Group – Shanghai China.”1125 Brachytherapy for Prostate Cancer”

Asia–Pacific Urological Association Annual Meeting – Beijing China

– Brachytherapy for Prostate Cancer

– Prostate Cancer and Sexual Dysfunction

2001

Victorian State Urology Meeting. Presentations on:

– Brachytherapy

– Prostate Cancer

– Peyronie’s Disease

– Grid Biopsy

Urological Society of Australasia (USA) – Annual Scientific Meeting

“Medico Legal Aspect of Prostate Cancer”

Australian Prostate Cancer Collaboration (APCC) ASM.

“Nomogram Validation for Prostate Cancer”

2002

Annual Australian Urological Meeting. Presentation on Prostate Cancer

NSW Urology Meeting. Presentation on Prostate Cancer.

National Prostate Cancer Symposium. Presentation on Prostate Cancer

2003

American Urological Association (AUA) Meeting – 2 presentations

Australian Annual Scientific Urology Meeting – 7 presentations

APCC – presentation on Prostate Cancer

Australian Brachytherapy Society –”Outcomes of High & Low Dose Brachytherapy”

Sloan Kettering Prostate Cancer Meeting – “Prostate Cancer Outcomes”

Eli Lilly Company Meeting –”Prostate Cancer & Erectile Dysfunction”

National Prostate Cancer Symposium –”Prostate Cancer & Surgery”

2004

Australian Brachytherapy Society – 2 presentations

Urological Society of Australasia – 2 presentations

Uro–Oncology Group of NSW – “Radical Prostatectomy”

Sydney University – Debate on Prostate Cancer

NSW Urology Meeting – 3 presentations

Australian–Israeli Chamber of Commerce – presentation on Prostate Cancer

2005

Australasian Urological Society – 2 presentations

Chinese Urological Society – 2 presenations

St Vincent’s Hospital “Steggles” Conference

Brachytherapy Symposium – 4 presentations

Asia Pacific Uro–Oncology Meeting – presentation on “HIFU”

World Health Organisation Symposium Paris –Presentation on Prostate Cancer.

NSW Urological Society Meeting – 2 presentations

2006

Australasian Urological Society – 3 presentations

NSW Urological Society Meeting – 4 presentations

7th National Prostate Cancer Symposium Melbourne

Presentation on “HIFU”

2007

Australasian Urological Society – 2 presentations

General Practitioners Continuing Education Annual Meeting – 3 presentations

Urology Oncology Group Meeting – 2 presentations

2nd International Robotic Symposium Ohio – 1 presentation

PCFA Men’s Health Promotion Forum – Prostate cancer treatment panel – radical prostatectomy (open, robotic & laparoscopic).

NSW Nurses Urological Society meeting – Topic: Prostate Cancer. October

2008

3rd International Robotic Symposium Orlando – 2 presentations. March

Laverty Pathology Men’s Health Conference for GPs – Topic: Prostate Cancer.

Nurses Surgical Symposium Westmead Hospital – “Prostatectomy & Robotic Surgery”.

General Practitioner’s Continuing Education Annual Meeting – Prostate cancer & PSA.

Prostate Cancer Foundation of Australia Hunter Region

Western Australian Urological Society National Annual Scientific Meeting –3 presentations.

Prostate Cancer Foundation of Australia 1st National Conference, Gold Coast “Future of Prostate Cancer”.

2009

18th Australasian Brachytherapy Group Annual Scientific Meeting, Gold Coast –1 presentation.

Australasian Urological Annual Meeting. Gold Coast – 3 presentations

2010

Australasian Urological Society Annual Meeting Perth –2 presentations and debate: “Robotic Assisted Laparoscopic Radical Prostatectomy is the Gold Standard Surgical Treatment for Prostate Cancer”.

5^th International Robotic Symposium Orlando. “Continence after robot radical prostatectomy”.

Integrative Medicine Society Meeting. “Integrative prostate cancer treatment” & “Robotics in prostate cancer surgery.”

11^th National Prostate Cancer Symposium Melbourne. August. “Continece post robotic radical prostatectomy”.

New Zealand Urological Meeting. “Prostate Cancer – How to choose” & “Robotic surgery”.

PCFA National Conference. “Prostate Cancer – How to choose” & “Side effects management”.

2011

NSW Section Urological Meeting, Sydney, November Point Counterpoint – Locally Advanced Prostate Cancer.

NSW Urological Nurses Conference, Sydney “How does one make a choice between different prostate cancer treatment modalities and robotic surgery”.

12th Australasian Prostate Cancer Conference (APCC), Melbourne, August. Master class in robotic surgery.

Trainee Week 2011 “Localised Prostate Cancer – What We Do Know, What We Don’t”. Factors in favour of robotic radical prostatectomy surgery.

General Practitioner Annual Symposium, Sydney, May.

1. Prostate cancer update

2. Benign prostatic hyperplasia update

The Inaugural international prostate cancer symposium – Weill Cornell Medical College New York.

1. Locally advanced prostate cancer

2. Benefits of robotic radical prostatectomy.

American Urological Society Annual Scientific Meeting. Washington, May.

1. Quality of Life

2. Transperineal biopsy of prostate

3. Locally advanced prostate cancer.

2012

• GlaxoSmithKline Australia Pty Ltd GP Dinner, March. “STEP UP – Do more for your patients with BPH”
• Friends of Israel Urological Symposium Tel Aviv May.
  1. Learning curve of robot assist prostatectomy.
  2. Nerve sparing radical prostatectomy – How do I do it – Bladder neck dissection and dissection of seminal vesicles.
• NSW State Parliament Sydney. “Prostate cancer update”.
• MRI of the Prostate – A Multidisciplinary Symposium. May. Sydney
  1. The role of MRI
  2. Screening and MRI
• The Australian Vietnamese Health Professionals Association NSW Inc. – Annual Scientific Conference. October. Sydney. PSA & Prostate Cancer Update.

2013

• 3rd Congress of Asian Pacific Prostate Society (APSS) – 13th April. Melbourne “How to improve continence & potency after robot-assisted radical prostatectomy”.
• St Vincent’s Campus Steggles Conference – April. Sydney
  1. Focal therapy – Are we ready?
  2. Biopsy techniques – TRUS v’s Transperineal
  3. 2 live cases presentation (Nanoknife & HIFU)

2014

• USANZ 67th Annual Scientific Meeting – The Role of MRI in the early detection of prostate cancer
• Asia Pacific Imaging Meeting – The role of MRI
• USANZ South Australian State Selection Meeting – Presentations on MRI & Focal Therapy
• USANZ NSW State Section Meeting – Presentations on salvage radical prostatectomy, MRI, Nanoknife
• Tolmar Lecture Series – Focal Therapy
• CME GP Talk September – Prostate Cancer Update

2015

• AUA New Orleans – May
  1. BAUS/BJUI/USANZ – The Role of focal therapy in localized prostate cancer; preliminary Australian results
  2. MRI Presentations
• Cleveland Clinic & Case Western Reserve University Ohio – May
  1. Transperineal biopsies
  2. Focal Therapy
  3. MRI
• RANZCR NSW Branch Education Evening – An update of MRI in prostate cancer
• NSW State Section Meeting – 7^th November
  1. Focal therapy
  2. Overview of prostate cancer imaging
• Royal Australian College of Surgeons NSW – 10th November Graham Coupland Lecture – “The Challenge of Prostate Cancer Care – Past, Present & Future”

2016

• USANZ Annual Scientific Meeting – MRI Education Course – Focal Therapy Debate
• European Meeting EAU – Two papers on PSMA PET Scanning
• Asian–Pacific Prostate Cancer Annual Meeting – New MRI Nomogram for Prostate Cancer
• Israel FOPI International Meeting. Nanoknife Update, Surgery versus Radiation Debate, Robotic RP Technique
• AUA. Focal Therapy – How to select
• Webinar – Diet and Prostate Cancer

2017

• USANZ 2017 – Focal therapy nanoknife and PSMA Imaging and MRI Imaging workshop
• Robotic Symposium – Potency preservation in Robotics
• PROSCA Portugal – Focal Nanoknife, Robotic RP
• Tasmania ASM – Prostate Cancer Update
• MRI Fusion Workshop – Co–convenor

2018

• Hadassah Medical Center Jerusalem – Key note speaker for salvage prostate cancer treatment
• Hadassah Hospital, Jerusalem – 3–week educational session and facility upgrading program. Work involved updating the robotic surgery program, nanoknife program, MRI–fusion program, brachytherapy program, multidisciplinary team, PSMA program, transperineal biopsy program and establishment of a link between Hadassah and St Vincent’s Hospital for research
• Australasian Student’s Surgical Conference – Robotic surgery
• National Robotic Symposium – Centralisation of robotic services
• National Cancer Institute – Introduction of NanoKnife to Amsterdam
• Netherlands Cancer Institute, Amsterdam – Operation of the DETECT probe for prostate cancer
• Global Congress on Prostate Cancer, Frankfurt, Germany – PSMA screening and NanoKnife treatment
• Friends of Israel Urology Symposium – Robotic Surgery, PSMA Screening and Nanoknife
• 38th Congress of the Société Internationale d’Urologie, Seoul, Korea – Ideal framework for the introduction of Nanoknife – Presented on behalf of Professor Stricker by Urology Fellow Dr. Alexandar Blazevski

2019

• 34^th Annual European Association of Urology Congress – Irreversible Electroporation (IRE) for Prostate Cancer – Presented on behalf of Professor Stricker by Urology Fellow Dr. Alexandar Blazevski
• 27^th St Vincent’s Campus Research Symposium – Improving both oncologic and functional outcomes in prostate cancer via innovations in imaging, robotics and biomarkers – Presented on behalf of Professor Stricker by Dr. James Thompson

2020
International Society of Radiologists (ISMRM) – virtual conference, Aug 2020. Keynote address on the clinical role of MRI in Prostate Cancer. The ISMRM virtual conference was attended by approximately 10,000 people worldwide.

European Annual Scientific Urology Meeting (EAU20V)– virtual conference, Jul 2020. Invited presenter to discuss the results to date of both cancer clearance of the primary tumour, recurrence rates, side effect profile and salvage surgery. Prof Stricker’s conclusion was that the intermediate results are very encouraging with a remarkably low side effect profile and Nanoknife focal therapy a strong contender for being one of the major technologies to potentially treat focal prostate cancer internationally.EAU20V was attended by almost 10,000 delegates worldwide.

The World Society of Robotic Surgery (SRS)– virtual conference, Aug 2020. Invited speaker along with other major experienced robotic surgeons from the Sloan Kettering (New York) and University College Hospital in London among others in the area of salvage robotic surgery.A video presentation involving 10,000 delegates attending worldwide.

Australian Section of the World Society of Robotic Surgeons (SRS) – virtual conference, Aug 2020. Keynote speaker presenting a talk on preserving sexual function after robotic surgery as well as the management of high–risk prostate cancer. Prof Stricker’s presentation was part of an Asia Pacific Group of Expert Robotic Surgeons asked to describe his technique of potency preservation during Robotic Prostatectomy. He also gave a keynote address on high–risk prostate cancer. During this presentation, he made particular mention of the increasing role of PSMA PET scanning and described one of his most recent projects – the DETECT trial which is using a Geiger counter to help detect cancer which has spread to microscopic nodal disease and outside of the prostate during the operation of robotic surgery.

2021

• RACS Annual Scientific meeting (ASC May 2021) – Urology Program (combined with General Surgery) – Invited speaker for Robotic Radical Prostatectomy & Hernia.
• Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium – EAU and AUA (invited presentation).

2022

• USANZ 74^th ASM (25-28 June 2022) –  Focal Therapy Workshop  and Convenor of 5 presentations
• MedEd GP Urology Conference (18^th  June 2022) – P Stricker – Presentation on Prostate Caner Treatments
• Angiodynamics International Symposium Barcelona (Mar 2022) – P Stricker presented three Talks on IRE

Professional Contribution

• Chief investigator of numerous pre–clinical and clinical research projects at St Vincent’s Campus.
• In 1994 established the St Vincent’s Prostate Cancer Clinical Database and Tissue Bank in conjunction with the Garvan Institute. These contain extensive clinical and pathological outcome data and have resulted in a comprehensive scientific and clinical source that has been acknowledged both nationally and internationally.
• Instigated the establishment of the St Vincent’s Hospital Prostate Cancer Group.
• Education and mentoring of other Urologists, Urology Fellows and PHD, ILP, Honour students in the area of prostate cancer treatments and procedures.
• Reviewing of Prostate cancer grants for NHMRC
• Cancer Council “Localised Prostate Cancer” book – Member of review committee for both editions.
• “Your Guide to Prostate Cancer” by Dr Prem Rashid – Member of peer review group.
• Member of the Australian Cancer Network working party that developed guidelines for the Management of Localised & Advanced Prostate Cancer. This has been published and was the first evidence–based publication through the network. This was supported by the NHMRC.
• Regularly reviews manuscripts on prostatic conditions especially prostate cancer for peer reviewed journals including Medical Journal of Australia, Medicine Australia and Australian Prescriber.
• Research Supervisor for PhD/Masters students – Dr’s David Quinn, Lisa Horvarth, Kris Rasiah, Ruban Thanigasalam, Kim Pryor, Andy Huo, James Symons, Richard Savdie and James Thompson.
• Supervisor of the Urology Fellow program at St Vincent’s campus.
• Director of the Australian Prostate Cancer Collaboration – a body that co–ordinates prostate cancer research nationally.
• Co–author with Prof. Kerryn Phelps of the first national “PSA for the General Practitioner” book. This book was distributed to all GP’s in Australia in 2004. An updated edition was written in 2008.
• Regular contributor to the “St Vincent’s Clinic Proceedings” Magazine on new developments and treatments for prostatic conditions.
• Advisor to the NSW Cancer Council (book reviews).
• Member of PSA review board – PCFA & NHMRC.
• Contribution to the British Journal of Urology International e–learning modules for prostate cancer
• Phase I study of NanoKnife for ablation of prostate cancer in intermediate risk patients (Sponsor: Angiodynamics, Inc.). clinical input and supervision in the study protocol and expert advice for the execution of the study and pathology.

Public Contributions

Prostate Cancer Support Network

• Along with Jayne Matthews was involved in the initiation of the first prostate cancer support group in Australia at St Vincent’s Hospital, Sydney. Has also been instrumental in the development of the Association of Prostate Cancer Support Groups throughout Australia and incorporating this in the Prostate Cancer Foundation of Australia.
• Invited guest speaker at many prostate cancer support groups in NSW and ACT.
• Guest speaker at the Inaugural NSW Men’s Health Promotion Conference organised by the Prostate Cancer Foundation of Australia.

Public Education Information Brochures

• Active member in an educational sense on prostate cancer issues through frequent contributions to newsletters, tapes/DVD’s and a series of books. “Lifebuoy” – St Vincent’s Campus prostate cancer support group newsletter and “Prostate News” – The Prostate Cancer Foundation of Australia.
• AMA prostate cancer guidelines.
• DVD for prostate cancer information for support groups (PCFA & personal).
• Cancer Council booklet on Prostate cancer.

Television, Radio and Newspaper Interviews/Articles

• Invited guest speaker on several community programs to discuss new developments in prostate cancer such as:– Television: 60 Minutes–Channel 9, “What’s Good for You”,”A Current Affair” and Prime Time News on all TV stations.– Radio: 2GB, John Laws, Dr John D’Arcy and ABC Radio national– Newspapers: Financial Review and the Sydney Morning Herald

Website Service

• Developed the official website for the St Vincent’s Prostate Cancer Rsearch Centre www.prostate.com.au

General Practitioner Education

• “PSA for the General Practitioner” – Co–author with Prof. Kerryn Phelps. This book was distributed to all G.P.’s throughout Australia.
• GPCE (General Practitioner Continuing Education) Annual Conference – regular invited speaker at the National Conference for GP’s held annually.
• Invited guest speaker at numerous GP groups both in metropolitan and rural areas.
• “Prostate Cancer for the General Practitioner” PSA Booklet Edition 2. Co–authored with Prof. Kerryn Phelps. This book was distributed to 21,500 GP’s and Specialists throughout Australia (2008).

Prostate Cancer Foundation of Australia

• Inaugural Director
• Been integral in raising funds and establishing policy as a Foundation member of the organisation.
• Contributed to the national “Be A Man” campaign to raise awareness of prostate cancer in the community.

Urology Nurses Education

• Along with the nurses at St Vincent’s Private Hospital, has constructed a diploma course in Urology, particularly in prostate cancer. This diploma course is now conducted annually.
• Invited guest speaker at several NSW & Australian Urology Nurses Society conferences on prostate cancer treatments.

International Teaching Program

Professional Teaching

1. Research Fellowship Program

Prof Stricker has been involved and indeed initiated the fellowship program through St Vincent clinical school for over 10 years in mentoring research fellows (Local and International).

• Can Huynh
  – Inaugural robotic fellow when St Vincent Prostate cancer Centre started the robotic prostate program in 2008.
  – Current: Urologist, Macquarie University clinic, Australia
• Michael Hoch (France)
  – Research areas/publications: Predictors of prostate cancers, benign prostatic hyperplasia and outcomes of treatments of prostate cancers.
  – Current: Urology Consultant and Surgeon, France
• Ziv Maianski (Israel)
  – Research areas/publications: Saw palmetto and lower urinary tract symptoms in men.
  – Current: Urologist, Luanda Medical centre, Israel
• Ruban Thanigasalam
  – Research areas/publications: Radical prostatectomy
  – Current: Associate Professor and Urological surgeon, Chris O’Brien Lifehouse, Australia
• Paul Chen
  – Research areas/publications: Radical prostatectomy
  – Current: Surgeon, Chris O’Brien Lifehouse, Australia
• Carlo Yuen
  – Research areas/publications: Radical prostatectomy, benign prostatic hyperplasia, treatments of prostate cancer, Imaging mpMRI and PSMA-11 PET/CT and Active surveillance
  – Current: Urology surgeon, St. Vincent’s Clinic, Australia
• Richard Savdie
  – Research areas/publications: Radical prostatectomy, robotic surgery and PSMA/mpMRI Imaging
  – Current: Urologist, St. Vincent’s Clinic, Australia
• Nicolas Doumerc (France)
  – Research areas/publications: Radical prostatectomy, robotic surgery
  – Current: Head of urology, Toulouse, France
• James Symons (2012)
  – Research areas/publications: Radical prostatectomy and treatments of prostate cancer
  – Current: Urologist, St Vincent’s Private Hospital and SAN clinic, Australia
• Tania Hossack (2012)
  – Research areas/publications: Radical prostatectomy
  – Current: Urology surgeon, Chris O’Brien Lifehouse, Australia
• James Thompson PhD (2012 – 2016)
  – Research areas/publications: Radical prostatectomy, treatments of prostate cancer, PSMA/mpMRI Imaging and Active surveillance
  – Current: Consultanting urology Surgeon, St George, St Vincent’s Clinic and Hurstville & Honorary VMO (St Vincent’s), Australia
• Lee Ponsky (USA) 2013
  – Research areas/publications: mpMRI Imaging and Focal Irreversible Electroporation (IRE)
  – Current: Professor and Chairman, Cleveland Medical Centre and Case Western Reserve University, USA
• Minh Tran (2014)
  – Research areas/publications: mpMRI Imaging, benign prostatic hyperplasia and Focal Irreversible Electroporation (IRE)
  – Current: Urologist fellow, St Vincent’s, Australia
• Pim Van Leeuwen (The Netherlands) 2015
  – Successful research grant: $759,000.00 Paul Ramsay Grant
  – Research areas/publications: PSMA/mpMRI Imaging and Focal Irreversible Electroporation.
  – Current: Urologist, Netherlands Cancer Institute, The Netherlands
• Francis Ting (2015)
  – Research areas/publications: PSMA/mpMRI Imaging and Focal Irreversible Electroporation (IRE)
  – Current: Urologist, Australia
• Amila Siriwardana (2016)
  – Awarded at USANZ Brisbane 2019 for contributions to PSMA PET/CT imaging research as part of Prof Stricker’s research team.
  – Research areas/publications: PSMA/mpMRI Imaging, Focal Irreversible Electroporation (IRE) abd radical prostatectomy
  – Current: Urology Consultant, RBWH, Australia
• Willemien van Den Bos (2016)
  – Research areas/publications: Focal Irreversible Electroporation (IRE) and MpMRI imaging
  – Current: Consultant and Interventional Radiologist, The Netherlands
• John Chang (2017)
  – Research areas/publications: PSMA/MRI Imaging and Focal Irreversible Electroporation (IRE)
• Anton Kalsbeek PhD (2014 – 2017)
  – Research areas/publications: Genomic markers and drivers of aggressive prostate cancer, PSMA/MRI Imaging and Focal Irreversible Electroporation (IRE)
  – Current: Urology Resident, The Netherlands
• Ilan Gielchinsky (Israel) 2017
  – Research areas/publications: MRI Imaging and Focal Irreversible Electroporation (IRE)
  – Current: Robotic surgeon, Israel
• Alexandar Blazevski PhD (2018)
  – Research areas/publications: Focal Irreversible Electroporation (IRE), PSMA/MRI Imaging, Robotic Surgery and Immunotherapy for prostate cancer
  – Current: Urology resident, Australia
• Matthijs Scheltema (The Netherlands) 2017
  – Research areas/publications: PSMA/MRI Imaging and Focal Irreversible Electroporation (IRE)
  – Current: Urology registrar, The Netherlands
• Brian Yuen (2018)
  – Research areas/publications: Active surveillance and Focal Irreversible Electroporation (IRE)
• Amer Amin (2019)
  – Research areas/publications: Active surveillance and Focal Irreversible Electroporation (IRE)
  – Current: Urology registrar, Australia
• William Gondoputro (2020)
  – Research areas/publications: Radical prostatectomy, DETECT study and Focal Irreversible Electroporation (IRE)
  – Current: Research fellow, St. Vincent’s, Australia
• Bart Geboers (2020)
  – Research areas/publications: Immunotherapy and Focal Irreversible Electroporation (IRE)
  – Current: Research fellow, St. Vincent’s, Australia and The Garvan Institute of Medical Research
• Paul Doan (2021)
  – Research areas/publications: Active surveillance and developing nomograms
  – Current: Research fellow, St. Vincent’s, Australia
• Athos (2022)
  – Research areas/publications: Active surveillance and developing nomograms
  – Current: Accepted in Urology Program
• Isabella Williams (2023)
  – Research areas/publications: Nanoknife
  – Current: Accepted in Urology Program
• Jason Jung (2023)
  – Research areas/publications: Nanoknife
  – Current: Research fellow, St. Vincent’s, Australia

2. PhD (UNSW)/Masters (USYD) Program

• David Quinn (PhD)
  Associate Professor of Medicine (Clinical Scholar) Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood Diseases in the Department of Medicine
• Lisa Horvarth (PhD)
  Director of research Chris O’Brien Lifehouse, Australia
• Kris Rasiah (PhD)
  Urology specialist, Australia
• Ruban Thanigasalam (Masters)
  Associate Professor and Urological surgeon, Chris O’Brien Lifehouse, Australia
• Kim Pryor (PhD)
• James Symons (Masters)
  Urologist, St Vincent’s Private Hospital and SAN clinic, Australia
• Richard Savdie (Masters)
  urologist, St. Vincent’s Clinic, Australia
• James Thompson (PhD)
  Consultant urology Surgeon, St George, St Vincent’s Clinic and Hurstville and VMO (St Vincent’s), Australia
• Anton Kalsbeek (PhD)
  Urology Resident, The Netherlands
• Francis Ting (Masters)
  Urologist, Australia

3. Urology Registrar Training program

Prof Stricker actively participates in supervising registrars in the training program for urological cancers at the St Vincent’s campus.

• Stuart Ehsman – Urologist (POW hospital, Australia)
• Peter Nash – Urologist (Hurstville, Miranda, St. Leonards, Australia)
• Graham Coombes – Urologist, (Mater hospital, Australia)
• Justin Vass – Urologist (St. Leonards, Australia)
• Paul Kovac – Urologist (Ramsay Healthcare, Australia)
• Paul Gassner – Urologist (Hurstville, Nowra, Sydney South West hospital, Australia)
• Ramin Samali – Urologist (Ramsay Healthcare, Australia)
• Michael Wines – Urologist (San Clinic, Australia)
• Hodo Hoximollo – Urologist (ACT, Australia)
• Jim Adshead – Urologist (Spire Harpenden Hospital, UK)
• Venu Chalasani – Urologist (St. Leonards, Australia)
• Charles Chabert – Urologist (QLD, Australia)
• Can Huynh – Urologist (Macquarie University clinic, Australia)
• Claire Whelan – Urologist (Central West, Australia)
• Anthony Hutton – Urologist (Hurstville, Miranda, Ashfield, Australia)

4. Student Teaching Program

• Students are regularlyi nvited to the Multidisciplinary Team Meetings (MDT) at St Vincent’s to learn from real patient cases with involvement of the multi-disciplinary teams.
• Attachment of Year 5 senior students as part of the UNSW Urology Rotating Program – Phase 3 attend consulting rooms and operating theatres for teaching.
  – Phui Yeng Chee (26-30 July 2021)
  – Howard Chow (23-27 Aug 2021)
• UNSW ILP
  – Max Leung (Mar 2023 – Dec 2023)
  – Allen Guo (Mar 2023 – Dec 2023)